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Abstract 
The introduction to this thesis covers the original work by McElroy, which 
established the requirements for light emission from firefly luciferin, and 
then the eventual elucidation of it chemical structure and synthesis. 
The mechanism of light emission is then discussed and a brief overview of 
some of the uses of bioluminescence in biology is discussed.  The 
limitations of firefly luciferin are described along with some of the methods 
and attempts to address the limitations 
The results and discussion section describes the various attempts and 
progress towards a new alkyne bridged luciferin analogue.  The various 
attempts to produce a new synthetic route to infraluciferin are described 
along with the successful route.  The synthesis of a new analogue using the 
new synthetic route to infraluciferin is then presented. 
The future work and conclusions section give a summary of the work left 
that still warrants more attention and the successful results that were 
attained. 
The experimental section provides procedures and data for all the relevant 
compounds from the research carried out.  
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Impact Statement 
Bioluminescence imaging (BLI) is a powerful method to visualise 
molecular and cellular features, in vitro and in vivo noninvasively.  
The enzyme luciferase produced by the firefly is able to emit light 
chemically from its small molecule substrate D-luciferin. Introduction of 
these two components into cells or whole animals produces light that can 
be captured by sensitive detectors. The simplicity of this imaging method 
has led to it becoming one of the most popular methods for in vivo 
monitoring of numerous diseases and cellular functions. 
The technique has been held back because the light emitted by D-luciferin 
is at λmax 557 nm, which is absorbed and scattered by tissue and 
haemoglobin, thus limiting its use in mammalian tissue. 
Previous work within the research group has led to an analogue of D-
luciferin called infraluciferin that emits light at λmax 706 nm, which is able 
to penetrate tissue and haemoglobin.  The original synthesis however was 
limited to small quantities of material, which prohibited large scale in vivo 
studies.  The synthesis did not allow for other analogues to be produced 
from the same method.    
A new synthetic route to infraluciferin was developed which can produce 
multi gram quantities, and enough material was produced to conduct a 
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large scale multiparametric in vivo mouse study.  The new synthetic route 
was also used to produce a new infraluciferin analogue. 
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Introduction 
1.0 The structure of luciferin 
The structure of luciferin 1 can be described as a benzothiazole moiety 2 
that is directly attached to a thiazoline moiety 3 (figure 1).  Both structures 
are linked via the carbon at the C2 positions, with the benzothiazole having 
an alcohol at the C6’ position and the thiazoline having a carboxylic acid at 
the C5 position  
 
Figure 1: Luciferin moieties 
1.1 Benzothiazoles in nature 
The benzothiazole moiety 2 is relatively rare in natural products, but has 
been observed ranging in complexity from benzothiazole itself (first 
isolated in 1967 from the volatiles of American cranberries Vaccinium 
macrocarpon Ait. var. Early Black), to more complex molecules such as 
the thiazo-rifamycins 4 (figure 2). 1 
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Figure 2: thiazo-rifamycin structure 
 
Since the initial isolation, benzothiazole has been isolated from a number 
of other sources including: - the tail gland of the red deer Cervus elaphus,  
sulfur volatiles in wines, volatile fraction of French oak wood used in the 
aging of wine, and was also seen in the aroma fraction of tea leaves, as well 
as in the flavor compound produced by the fungi Aspergillus clavatus. 2–4 
1.2 Rifamycins   
The rifamycins are a group of naturally occurring antibiotics that are 
synthesized by the bacterium Nocardia mediterranei. They are a subclass 
of a larger family known as the ansamycins. Rifamycins are particularly 
effective against mycobacteria, and are therefore used to treat diseases such 
as tuberculosis and leprosy. Rifamycins were first isolated in 1957 from a 
fermentation culture of the bacterium Nocardia mediterranei at the Lepetit 
laboratory in Milan,5  seven rifamycins were discovered, including the 
parent molecule rifamycin S 5.6 Cricchio and coworkers reported the 
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isolation of two benzothiazole containing rifamycins from mutant strains of 
Nocardia mediterranei.7 These rifamycins are known as thiazo-rifamycins, 
namely rifamycin P 6 and rifamycin Q 7 (figure 3).  
 
Figure 3: rifamycin P and Q 
 
As part of the same research Cricchio and coworkers described the 
synthesis of rifamycin P and rifamycin Q from rifamycin S (Scheme 1).  
By reacting rifamycin S with cysteine methyl ester hydrochloride, 
intermediate 8 was obtained quantitatively, and then oxidized using 2,3-
dichloro-5,6-dicyano-1,4- benzoquinone (DDQ) to give the benzothiazole 
motif 9 in 20% yield. The same intermediate 9 could be obtained directly 
by reacting rifamycin S with only 0.5 equivalent of cysteine methyl ester 
hydrochloride, using the excess of the rifamycin S quinone as an oxidant. 
The common intermediate, methyl benzothiazole-2-carboxylate 9, gave 
benzothiazole (rifamycin P) 6 by alkaline hydrolysis and decarboxylation, 
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or rifamycin Q 7 by reduction using lithium aluminium hydride.  
 
Scheme 1: synthesis of rifamycin P and Q 
 
 
1.3 Benzothiazoles from Marine Sources  
 
A novel β2- adrenoceptor-selective agonist was isolated in 1999 by a 
Japanese group from the marine sponge Dysidea sp., the benzothiazole 
S1319 10 (figure 4).8 β2-Adrenoceptor agonists are used as anti-asthmatic 
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drugs, and S1319 10 was the first example of a sponge-derived 
bronchodilator. Structurally, the molecule is closely related to the 
endogenous ligand adrenaline 11 (figure 4).  
 
Figure 4: S1319 and adrenaline 
The syntheses of this naturally occurring bronchodilator has been 
reported,9,10 that involved a directed lithiation/benzyne-mediated 
cyclization reaction (scheme 2). Aryl ether 12 was prepared efficiently 
from the commercially available 2,5- fluoronitrobenzene by displacement 
of the more activated fluoride via an SNAr reaction with potassium tert-
butoxide. Reduction of the nitro group to the aniline, followed by 
conversion to the isothiocyanate and addition of 2-propanol allowed the 
formation of thiocarbamate cyclization precursor 13 in 64% over three 
steps. Exposure of 13 to directed-lithiation/benzyne-mediated cyclization 
conditions, followed by quenching of the anion by addition of the readily 
prepared Boc-protected sarcosine-derived aldehyde 14 gave the expected 
benzylic alcohol 15. The final step to produce S1319 10 was achieved by 
global deprotection using trifluoroacetic acid.  
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Scheme 2: Synthesis of S1319 
 
 
 
1.4 Thiazolines in nature 
Biologically active Thiazonlines found in natural products are often 
multiple and directly linked, such as tantazoles 16, mirabazoles 17, and 
thiangazole 18 (figure 5).  
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Figure 5: tantazoles, mirabazoles, and thiangazole structures 
  
Mirabazoles and tantazoles were isolated from blue- green algae 
Scytonemea mirabile and are studied for their cytotoxic and anticancer 
properties.11 Thiangazole was isolated from a metabolyte of Polyangium 
spec. strain P13007 and studied for its anthelmintic and antiviral 
properties.12,13 Due to their unusual structure and their biological properties, 
these compounds have aroused great interest for organic chemists, and 
many have been target for total synthesis. More than one thiazoline ring (2, 
3, or 4) is contained in these compounds, and in most cases the starting 
sulfur-containing precursor used for thiazoline ring formation is the 2-
methylcysteine 19 and 20, which is available from the chiral pool as the 
S
N
NS
S
N S
N
R1
R2
(-)-Mirabazole A, R1= H, R2 = Me
(-)-Mirabazole B, R1= Me, R2 = Me
(-)-Mirabazole C, R1= Me, R2 = H
S
N
NS
S
N S
N
R2
R1
(-)-Tantazole A, R1= H, R2 = Me
(-)-Tantazole B, R1= Me, R2 = Me
(-)-Tantazole C, R1= Me, R2 = H
O
NHMe
S
N
NS
S
N S
N
R2
R1
(-)-Thiangazole A,
O
NHMe
Ph
16 17
18
University College London 15 
(R) or (S) enantiomer with a free or protected thiol function. 
S-Benzyl-protected amino thiols were used by Heathcock for preparation of 
thiazolines in the total synthesis of (-)- Mirabazole C 21 (scheme 3) 14 
 
 
Scheme 3: Mirabazole C synthesis 
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(R)-N-(Carbobenzyloxy)-S-benzyl-2-methylcysteine 19 and the 
hydrochloride salt of the corresponding methyl ester 20 were coupled using 
bromotris(pyrroli- dino)phosphonium hexafluorophosphate (PyBroP)6 as 
the condensation reagent  to obtain the dipeptide 21. The carbobenzyloxy  
group was removed  by treatment with HBr in acetic acid, and the resulting 
amine was coupled with 19 to afford tripeptide 22. Once again the 
carbobenzyloxy group was removed  and the resulting amine was acylated 
with isobutyryl chloride to obtain 23. Saponification of the methyl ester 
gave the free acid, which was treated successively with p-toluenesulfonyl 
chloride and  S-(benzylamino)ethanethiol to obtain 24. The benzyl groups  
were removed by  treatment owith sodium in ammonia and the resulting 
tetrathiol treated with titanium tetrachloride in DCM to obtain  
dihydromirabazole.  The terminal thiazoline ring  was oxidized by  nickel 
peroxide 7 to (-)-mirabazole C  21.  
 
1.5 Discovery and light emission requirements 
The compound that is responsible for the light emitted from the firefly of 
the Lampyridae family is known as D-luciferin 1.  Its bioluminescent 
properties (emitting light at λmax 558 nm) have been widely used in small 
animal studies for the visualisation of various cellular functions.   
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McElroy was the first to report that extracts from the firefly were capable 
of emitting light for short periods in the yellow/green spectrum, and to 
show that addition of adenosine triphosphate (ATP) could prolong the light 
emission. He hypothesised that the energy required for light emission came 
from the phosphate bond and building on these early studies he continued 
to identify the role of ATP, Mg2+, O2 and the enzyme luciferase as being 
essential for light emission in the firefly (Scheme 4). 15 
 
 
Scheme 4: McElroy’s proposed light emission  
 
 
1.6 Mechanism of bioluminescence from D-luciferin 
A detailed mechanistic study of the process of light emission involving D-
luciferin proposed that a dioxetanone intermediate 23 is a key step in the 
process (scheme 5).16 
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Scheme 5: Bioluminescent mechanism of D-luciferin 16 
 
Once bound in the luciferase active site the anion of luciferin 24 takes part 
in nucleophilic attack on the α-phosphoryl group of the carboxylate ATP-
Mg2+ complex 25, to form the adenylated luciferin 28.  Proton abstraction 
from the adenylated luciferin allows the molecule to interact with 
molecular oxygen to form the hydroperoxide anion 29, which is able to 
cyclise and form dioxetanone 23, as AMP is a good leaving group.  The 4-
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membered ring formed is unstable and the O-O bond is weak which results 
in the collapse of the ring with release of CO2 and the formation of 
oxyluciferin 22 in an exited state.  It is the relaxation of this molecule to the 
ground state which releases a photon of light.  Whether the light is emitted 
from the keto 22 or enol form 24, or whether each is responsible for 
different wavelengths are the subject of various studies, which are ongoing. 
1.7 SET oxidation mechanism 
Branchini et al. have proposed a single electron transfer mechanism, which 
they have supported with EPR experiments confirming the presence of the 
superoxide anion seen in 30 (scheme 6). 
 
Scheme 6: SET oxidation Mechanism 
 
This mechanism which still leads to the dioxetanone 23 from 30 is more 
plausible given that molecular oxygen exists as triplet oxygen shown in 31, 
and attack by a nucleophile (scheme 5) leads to a spin forbidden process.17 
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1.8 Bioluminescence in biology 
The light emitted from various bioluminescent sources has been utilised to 
visualise a multitude of cellular functions, which would either not be 
possible or would be highly invasive in vivo.  The luciferin luciferase 
system has for example been used in reporter gene assays to study G-
protein coupled receptors.  By placing a luciferase gene under the control 
of the desired promoter sequence; it is possible to monitor the gene 
expression controlled by that promoter by luciferase expression and 
subsequent light emission with D-luciferin.18 Apoptosis and proteosome 
activity have been studied by generating a pro-luciferin analogue which 
emits lights that is dependent upon the enzymatic activity which occurs via 
the specific proteases under investigation.19 20 
Fluorescence has been used as an optical reporter by genetically encoding 
florescent proteins in a similar fusion to that used for the luciferase 
enzyme.  Modified florescent dyes can also be constructed in such a way 
that they are able to be cleaved by specific enzymes under investigation.21 
Bioluminescence however has some advantages over fluorescence; most 
importantly an external photon is required to excite the florescent molecule 
for light emission to occur as opposed to the biologically catalysed reaction 
for the luciferin/luciferase system.  It is this external process that limits the 
University College London 21 
fluorescence reporter method, as haemoglobin can absorb visible light.22 
Another disadvantage is that as well exciting the fluorophore any other 
chromophores could be excited which results in high background signal to 
noise ratio.  The external light source can also damage these molecules 
causing damage to cells or even cell death.  Auto-luminescence and photo 
toxicity are not an issue with bioluminescence as well as having a high 
signal to noise ratio.     
The most commonly used bioluminescent system is D-luciferin and beetle 
luciferase, but coelenterazine with renilla reniformis luciferases have been 
used in the past.  Coelenterazine however has some disadvantages to D-
luciferin; it is a much larger molecule and less water soluble.  It is also 
more toxic than D-luciferin and this limits its use in vivo.  Because 
coelenterazine does not require activation via adenylation there is a 
tendency for auto activation and therefore higher background 
luminescence.23 For these reasons the D-luciferin with firefly luciferase is 
the most used system as a bioluminescent reporter in biological sciences. 
 
1.9 Limitations of firefly luciferin 
The Luciferase/D-luciferin system for imaging of biological events is not 
with out its limitations.  Although relatively inexpensive and efficient it is 
only suitable for small animals as the natural firefly bioluminescence 
University College London 22 
system produces only yellow-green light (λmax = 560 nm). Cellular 
components and other endogenous molecules such as hemoglobin, absorb 
visible light.24 22 Therefore, a large portion of the light emitted by luciferase 
is absorbed by the surrounding tissue and will not penetrate through the 
animal for detection.  
The tissue attenuation of the light generated by the reaction of luciferin 
with luciferase can be overcome by a red and far-red emission that greatly 
improves the detection in small animal imaging.10 Near- infrared (near-IR) 
light (650-900 nm) is less well absorbed by these endogenous molecules 
and is able to further penetrate through tissue. Modifying either the 
luciferase enzyme or the natural substrate D-luciferin can lead to a red-
shifted emission. 
Diverse factors can impact the wavelength of light emitted with D-
luciferin. For example, the presence of divalent cations, such as Cd2+ and 
Zn2+, can red-shift the peak wavelength of light emitted with firefly 
luciferase. Additionally, lowering the pH of the solution to ~6, or 
increasing the temperature of the solution from ambient to 37 °C also red 
shift the emission profile. Finally, the origin of the luciferase can impact 
the wavelength of light emitted. The railroad worm luciferase from the 
lateral lanterns of Pyrearinus termifiuminans catalyzes emission of green 
light (542 nm), while the luciferase from the head lanterns of results in red 
University College London 23 
light emission (628 nm).25 In a laboratory situation the environmental 
parameters can be readily manipulated.  Living organisms however hold 
the concentration of divalent cations, pH, and temperature to their optimum 
levels. Therefore, the luciferase and luciferin are the preferred targets for 
altering the emission profile in vivo.  
 
1.10 Synthesis of Luciferin 
The empirical formula of luciferin was deduced in 1957 by elemental 
analysis that was conducted on luciferin isolated by Bitler and McElroy 
from 15,000 fireflies, which yielded 9 mg of crystalline D-luciferin.26 The 
first synthesis was reported in 1961 by Seliger et al confirmed that the 
molecule contained both a benzothiazole and thiazoline ring.  With the use 
of L or D-cysteine they produced both enantiomers and showed that the 
natural L isomer did not emit light when subjected to the protocols 
developed previously of adding luciferase, ATP, Mg2+ in the presence of 
oxygen to the substrate.  In fact they found that L-luciferin inhibits the 
emission of light.  The luciferase enzyme is unable to distinguish between 
the two enantiomers and adenylates both molecules equally but the L 
enantiomer is not oxidised and remains bound in the active site. 27 28 
Luciferin (D/L-2-(6-hydroxy-2-benzothiazol-yl-)-∆-thiazoline-4-carboxylic 
acid) was first synthesised by White et al.  In this procedure, p-anisidine 32 
University College London 24 
is the starting material that, through intermediates 33 and 34, is transformed 
into the thioacid 35, in turn cyclized to 6- methoxybenzothiazole-2-
carboxylic acid 36. From this benzothiazole derivative, 2-cyano-6- 
hydroxybenzothiazole 37 is prepared in four steps. Compound 37 is the key 
intermediate for the synthesis of 1 that can be obtained almost 
quantitatively by reaction with D-cysteine (Scheme X). 28,29 
 
 
Scheme 7: First synthesis of luciferin 
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The overall yield of D-luciferin 1 from p-anisidine 32 is 9% through nine 
steps.  The synthetic approach described by White et al. is still more or less 
used for the preparation of 1 and related compounds. As previously stated, 
2-cyano-6- hydroxybenzothiazole 37 is the key intermediate for the 
synthesis of 1 and the most reliable procedure to obtain this compound is 
the demethylation of 2-cyano-6-methoxy derivative 38. 
This reaction can be most efficiently accomplished by fusion at 220 °C 
with pyridinium hydrochloride (Py.HCl). In these conditions, the labile 2-
nitrile moiety is kept intact and alternative procedures lead to hydrolysis of 
the cyano group. Other procedures are described for the synthesis of 2-
cyano-6-methoxybenzotiazole 38. According to Seto et al.30 6- 
methoxybenzothiazole-2-carboxyamide 39 is prepared from the 4-
methoxythioxanilinamide 40 by oxidative cyclization with alkaline 
K3[Fe(CN)6]. The transformation of compound 10 into the nitrile 38 has 
been carried out essentially as reported by White et al.31 (scheme  8). 
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Scheme 8: Synthesis of nitrile 38 
 
This experimental protocol has been applied to the preparation of 5-10 g of 
D-luciferin 1.32 The preparation of 4-methoxythioxanilinamide 40, 
according to Seto et al 30 can be carried out in good yields from p-anisidine 
32 and carbamoylthiocarbonylthioacetic acid 41. However, this compound 
is unstable and has to be prepared in situ, as described in detail by Bowie.32 
The experimental procedure allows 40 to be prepared from p-anisidine 32 
with an overall 39% yield (scheme 9).  
 
Scheme 9: Synthesis of 4-methoxythioxanilinamide 40 
 
According to another synthetic approach, 2-amino-6-methoxybenzothiazole 
42 can be prepared from p-anisidine 32, 33 and different routes can lead to 
2-cyano-6-methoxybenzotiazole 38 using a classical Sandmeyer reaction. 
In a first synthesis,33,34 2-chloro-6- methoxybenzothiazole 43 was prepared 
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by reaction of compound 42 with nitrous acid and HCl. Reaction of 
compound 43 with KCN in DMSO afforded the nitrile 38 (scheme 10).  
 
Scheme 10: improved synthesis of 38 
Conditions of formation of 2-chloro derivative 43 were improved using 
isoamyl nitrite and copper (II) chloride in polyethylene glycol 200 as 
solvent and yields were improved to 56%.35 More recently, the Sandmeyer 
reaction was carried out by direct introduction of cyanide with CuCN/KCN 
and following this approach a 41% yield was obtained. 35 
 
1.11 Red-shifting firefly bioluminescence via luciferin 
The emission of longer wavelengths than D-luciferin can be achieved either 
through bioluminescence resonance energy transfer (BRET), which uses 
the energy of the excited state oxyluciferin to excite a second fluorophore 
that will then emit light at an even longer wavelength.36 This technique is 
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often used to measure protein-protein interactions, since the donor 
luciferase and the acceptor fluorophore must be in close proximity.  By 
either directly labeling firefly luciferase with a near-IR fluorophore,37 or 
conjugating the luciferin to a near-IR dye,38  BRET can be a source of near-
IR light. The need to modify luciferase with a near-IR dye limits its use as 
a genetically encodable reporter.  Attaching a near-IR dye to the luciferin 
will limit water solubility and cell permeability of the luciferin.36 Reported 
analogues which include fluorophores to give a maximum emission > 600 
nm up to 675 nm.15 The donor luciferin-acceptor fluorophore configuration 
red shifts emission of the donor luciferin by intramolecular 
bioluminescence resonance energy transfer to the acceptor fluorophore.  
There is however a loss of signal intensity with BRET that may counter any 
benefit from the red shift in peak wavelength.  
A more direct method to increase the wavelength of light emitted is by 
chemical modification of the luciferin substrate itself.  The energy 
difference between the excited and ground states of the molecule 
determines the wavelength of light emitted.39 A number of analogues of 
luciferin have been reported in the literature (scheme 11).  Both L-luciferin 
44 and dehydroluciferin 45 do not produce light with luciferase and 
actually competitively inhibit the production of light when D-luciferin is 
also present.11   
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Replacing the 6ʹ-hydroxyl of D-luciferin with a more electron donating 
amino group red shifts the peak wavelength of light emitted.40 The three 
hydroxyl positional isomers of luciferin, O-methylluciferin, 5,5’-
dimethylluciferin and decarboxyluciferin were all inactive.12 A number of 
analogues have been reported to display considerably red-shifted 
bioluminescence spectra these include D-quinolylluciferin (46, λmax = 608 
nm) 5 and 6-aminoluciferin (47, λmax = 605 nm).  Alkyl amino substituents 
are more strongly electron-donating than either the original hydroxyl or the 
amine, which red shifted the peak emission wavelength even more. Maki et 
al. have reported amino derivatives in which the benzothiazole unit has 
been replaced with a conjugated aromatic ring (48, 49, 50). 14 The 
bioluminescence spectra of the more conjugated compounds is reported to 
be red-shifted (48, λmax = 445 nm; 49, λmax = 565 nm; 50, λmax = 688 nm) 
although the emission intensity is decreased 1000-10000 times compared to 
luciferin. Miller et al. report the synthesis of some amino derivatives of 
luciferin 1. 15 They found that the unsubstituted amino derivative 51 gave a 
maximum emission at λmax = 593 nm compared to the 605 nm reported by 
White. By changing the substitution on the amino group the maximum 
emission could be red-shifted further (51, R1= Et, iPr or nBu, R2=H, λmax = 
607 nm; R1, R2= Me, λmax = 607 nm).  
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Scheme 11: Analogues of luciferin reported to red-shift light with luciferase. 
 
Branchini et al. was one of the first to alter the core of D-luciferin. They 
showed that it was possible to exchange the benzothiazole of D-luciferin 
for either a naphthalene or quinolone 52. 41 These luciferins emit light upon 
treatment with firefly luciferase at 524 nm and 608 nm, respectively, albeit 
at a lower intensity than D-luciferin. Subsequently, others have developed 
electronically modified luciferins by substituting single atoms in either the 
benzothiazole or thiazoline rings of D-luciferin (scheme 12).42–44All remain 
substrates for luciferase and display altered emission profiles, but none 
improve on the bioluminescence obtained with D-luciferin.  
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aromatic system with extended π-conjugation to the thiazoline ring 53. 45 
This strategy produced the first example of a peak emission wavelength in 
the near-IR, at 675 nm. However, as with all the other synthetic substrates, 
shifting the peak wavelength is accompanied by a loss of signal intensity. 
While all of these new substrates demonstrate how promiscuous luciferase 
is, no example of a synthetic luciferin has shown improvement over WT 
luciferase and D-luciferin in terms of quantum yield under saturating 
luciferin and ATP conditions.   
 
 
Scheme 12: Analogues of luciferin 2. 
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1.12 Properties of D-luciferin and its analogues 
An added benefit of many synthetic luciferins is increased cell permeability 
and/or higher affinity for luciferase. When used in live cells and organisms, 
firefly luciferase will be retained inside the cell. Therefore, a luciferin must 
first cross the membrane in order to emit light. D-luciferin is small and 
relatively polar, therefore it is capable of moderate diffusion across cell 
membranes. However, D-luciferin only has a modest affinity for luciferase 
(Km = ~7 µM) and is thus unlikely to reach saturating conditions when 
used in live cells and organisms. Many of the synthetic luciferins 
developed thus far show-increased hydrophobicity relative to D-luciferin, 
which should increase cell permeability. Cyclic alkylamino luciferins also 
have increased affinity for luciferase (Km < 0.1 µM), allowing sufficient 
substrate to enter the cells to saturate the enzyme. 44 
 
 
1.13 Scope of research 
The aim of this project is to synthesise analogues of the bioluminescent 
molecule luciferin, which is found in the firefly.  Previous synthetic 
successes in the research group have produced an analogue of luciferin 
known as infraluciferin 54 (figure 6) that emits light at a wavelength that is 
able to penetrate body tissues (at 706 nm it is the furthest red shifted 
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analogue to date), and therefore has the potential to be used for deep tissue 
in vivo imaging. 46  
 
 
Figure 6 infraluciferin 
Our first aim was to improve on the original synthetic route (which is 
detailed in chapter 3) to obtain larger quantities of material for further 
biological assays, and also produce a route that would allow for other 
analogues to be more easily accessed from the same methodology.  One the 
reasons for the development of new analogues is that infraluciferin, as well 
as all the other analogues produce by various research groups which red 
shifted the wavelength of light emitted, have suffered from reduced 
quantum yields.    
There has been extensive work carried out on the effect that the luciferase 
enzyme plays in colour tuning of luciferin.  It would seem that the degree 
of deprotonation of the phenolic group at C-6 can affect the keto binding 
interaction at the other end of the molecule, by charge being delocalised 
through the extended π-system.  We believe that the increased conjugation 
N
S
O
OH
N
SHO
54
University College London 34 
of infra-luciferin compared to D-luciferin is responsible for the shift in light 
emission towards the red spectrum.47 
The shape of the luciferin molecule is of interest, as it will affect the fit of 
the substrate in the active site. Continuing on from the previously 
synthesized infraluciferin 54 we would like to investigate the luciferin 
analogue with an alkyne bridge connecting the benzothiazole and thiazoline 
rings.  This would have an extended π-system retaining the conjugation 
through the molecule (which is vital for light emission) but a subtly 
different shape being linear instead of bent, and could lead to different 
binding interactions within the active site.46 
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Results and Discussion 
2 Alkyne bridged luciferin analogue  
2.1 Sonogashira route to alkyne bridged luciferin 
 
Figure 7: Alkyne bridged luciferin analogue 
To synthesize the luciferin analogue 55 we proposed a Sonogashira 
disconnection to yield 56 and 57.  The thiazoline with a terminal alkyne 57 
could be produced from the condensation reaction of cysteine 58 with 
propiolonitrile 59 (scheme 13).  The Sonogashira reaction, which generally 
utilizes palladium and copper to catalyze the reaction between terminal 
alkynes and aryl halides, would be used to couple 56 and 57.  
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Scheme 13: Proposed Sonogashira route to 55 
 
For this route the focus was first on the synthesis of the thiazoline 57, and 
for this we needed to produce propiolonitrile 59.  Following the method 
used by Halter et al for the synthesis of this nitrile, the methyl ester 
propiolate 60 was converted to the amide using liquid ammonia to give the 
propiolamide 61, this was then treated with phosphorus pentoxide to yield 
propiolonitrile 59.48 It was hoped that 59 could be reacted with cysteine to 
form the thiazoline with a terminal alkyne 57, this was unsuccessful and the 
result of repeated attempts showed a double bond in the 1H NMR [δ 7.51 
(d, J = 10.5 Hz, 1H), 5.60 (d, J = 10.5 Hz, 1H] that suggested conjugate 
addition to 59 possibly by the sulfur of cysteine to give 62 (scheme 14).  
 
 
Scheme 14: Attempted synthesis of thiazoline 57 
 
2.2 Alternative Sonogashira route to alkyne bridged luciferin 
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An alternative disconnection places the terminal acetylene on the 
benzothiazole 63. This terminal acetylene could then be coupled to a 
preformed thiazoline with a good leaving group 64 via the Sonogashira 
reaction (scheme 15).   
 
 
 
Scheme 15: Proposed second route to 55 
 
Although there is no literature precedent for the Sonogashira reactions with 
thiazolines it would be an ideal reaction, and there is vast literature 
precedence for coupling terminal alkynes to various substrates bearing 
either a halogen or triflate as a leaving group, to form a carbon-carbon 
bond. 
A possible thiazoline had been produced by Schmitz and Romo which had 
ethyl ester attached as well as a triflate 64 (figure 8). 49 
 
Figure 8: Thiazoline with leaving group 
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There are several reagents, which are capable of converting aldehydes in to 
our desired alkyne, including the Corey-Fuchs and the Seyfeth-Gilbert 
reagents.  However the Ohira-Bestmann reagent 65 is able to produce the 
functional group inter conversion under mild conditions (scheme 16). 50 51, 
52 
 
 
Scheme 16: Conversion of aldehyde to terminal alkyne using the Ohira-Bestmann 
reagent 
 
As we have previously produced suitable benzothiazoles with attached 
aldehydes within the research group it was decided to attempt this route.  
The commercially available 6-methoxy-2- methylbenzothiazole 66 was 
treated with selenium dioxide to give the aldehyde 67 (64% yield, Lit. 
yield53 50 %) (scheme 17). 53 
 
Scheme 17: Synthesis of benzothiazole bearing terminal alkyne 
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The aldehyde 67 was converted to the alkyne using conditions previously 
utilised by Muller to give the novel alkyne 68 in 44 % yield after 
purification by column chromatography (scheme 18).51 Alkyne formation is 
clearly seen in 1H NMR by loss of the aldehyde peak at δ 10.10 and the 
appearance of the terminal alkyne peak at δ 3.56.   
 
 
 
 
Scheme 18: aldehyde to alkyne formation 
 
The Ohira-Bestmann reagent 65 was chosen, as the conditions employing 
potassium carbonate as a milder base were more suitable for use with the 
benzothiazole structure. The synthesis of the Ohira-Bestmann reagent was 
completed in three steps according to the procedure by Pietruszka and 
Witt.52   Starting with chloroacetone 69 and trimethyl phosphite to yield the 
Horner–Wadsworth–Emmons type product dimethyl 2-
oxopropylphosphonate 70.  The azide 71 was formed from 
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acetamidobenzenesulfonyl chloride 72 under phase transfer conditions 
using tertiarybutylammonium chloride (TBAC). Azide 71 was then utilised 
as a diazo transfer reagent for the previous oxophosphonate product 70, 
following deprotonation with sodium hydride to give the Ohira-Bestmann 
reagent 65 (scheme 19).  Yields for all three steps were within 5-10% of 
that stated in the literature.  The final product 65 was judged to be >90% by 
1H NMR and as noted in the literature was used as isolated in further 
reactions. 
 
 
 
Scheme 19: Synthesis of the Ohira-Bestmann reagent 52 
 
With the alkyne in hand our attention was turned to the synthesis of the 
thiazoline to be coupled with the alkyne.  Following the procedure by 
Schmitz and Romo treatment of cysteine ethyl ester 72 with triphosgene 73 
gave the thiazolidinone 74.  The desired thiazoline 64 with a triflate leaving 
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group was formed by treatment of 74 with triethylamine and triflic 
anhydride (49 % yield, Lit. yield 49 56 % over 2 steps) (scheme 20).49  
 
Scheme 20: Synthesis of thiazoline with triflate leaving group   
 
With both halves of the luciferin analogue in hand a Sonogashira coupling 
was attempted under standard literature conditions (scheme 21).54 
However, these initial reactions were unsuccessful, yielding only 
decomposed starting material. 
 
 
Scheme 21: Sonogashira coupling reaction54  
 
A survey of Sonogashira coupling reactions showed that subtle changes to 
the base, solvent and temperature could have drastic effects on the reaction, 
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an attempt to find conditions that would afford the desired compound 75 
(Table 1).55 No product was observed under any of the conditions screened, 
giving either un-reacted starting material or decomposition.  
 
 
 
 
Table 1: Conditions for Sonogashira coupling reaction 
 
Catalyst Equivalents Base Solvent Temp °C 
PdCl2(PPh3)2/CuI 5-10 % / 10  %  Et3N THF Rt-120 
     PdCl2(PPh3)2/CuI 5-10 % / 10  % Et3N THF rt - 120 
Pd(PPh3)4/CuI54 5-10 % / 10  % 2,6 lutidine DMF rt- 120 
Pd(PPh3)4/CuI54 5-10 % / 10  % 2,6 lutidine Dioxane rt- 65 
(PPh3)2Pd(OAc)2 5-10 % / 10  % NaOAc DMF 40-60 
 
 
With no encouraging results from these reactions, and the quantity of 
alkyne 68 depleted it was decided that it would be best to test the reactivity 
of the alkyne 68 and the thiazoline 64 separately. Under standard 
Sonogashira conditions (Scheme 22) the alkyne 68 was reacted with 
iodobenzene 76 which gave 77 in good yields. 
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Scheme 22: Sonogashira test reaction with 68 
Reaction of thiazoline 64 and terminal acetylene 78 under standard 
Sonogashira conditions was unsuccessful (scheme 23). 
 
 
 
Scheme 23: Sonogashira test reaction with thiazoline 64 
 
Further examination of the literature found few examples of triflates as 
leaving groups in Sonogashira reactions.  It was decided to attempt to 
synthesise the desired thiazoline with a halide as the leaving group.  There 
are numerous examples of halogenations of alcohols in the literature, which 
would be possible from 79 as the structure can potentially tautomerize to 
80 (scheme 24). 56 57 
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Scheme 24: Halogenation of 79/80 
Various attempts at halogenation were unsuccessful (Table 2).57 58 56 59 60   
In all the attempts no product was able to be isolated, with either starting 
material unreacted, formation of the thiazole, degradation or a complex 
mixture of all three  
 
 
Table 2: Conditions for halogenations of 79/80 
Reagent Solvent Temp °C Result 
POBr356 None 0-130 SM-azole/degraded 
CCl4/PPh3 Acetonitrile 0-65 SM-azole 
Bu4NBr/P2O5 Toluene 0-100 SM-azole/degraded 
Oxalyl Chloride/DMF DCM Rt-45 SM-complex mixture 
PPh3/CBr461 Toluene 0-125 SM-azole/degraded 
POBr357 Toluene 0-135 SM-azole/degraded 
PPh3/BrCCl3 DCM rt azole 
PPh3/Br3CCOCBr3 DCM rt azole 
PPh3/Br3CCO2Et DCM rt azole 
 
 
There is literature precedence for a CCl3 group acting as a leaving group 
and we proposed that thiazoline 81 could be synthesized as shown in 
scheme 25.62 Attempts to synthesize this compound did not produce the 
product, giving only unreacted starting materials and degraded products.  
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Scheme 25: Attempted thiazoline formation 
There are numerous examples in the literature which show a benzothiazole 
with a halide 82 taking part in a Sonogashira coupling reaction (scheme 
26).63   
 
Scheme 26: Sonogashira coupling with benzothiazole halide 
 
There is also a literature example of C-H activation with a benzothiazole 
bearing a proton 83 being directly coupled to an alkyne (scheme 27). 64  
 
 
Scheme 27: C-H activation coupling of benzothiazole and alkyne 
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With these studies in mind we hypothesized that the thiazoline 84 might 
show the same reactivity as benzothiazole 83 to give a thiazoline with the 
alkyne attached, and then undergo a Sonogashira coupling with a 
benzothiazole/halide such as 82.  The precursor thiazoline was synthesized 
from cysteine ethyl ester 72 and triethylformate 85, in quantitative yields 
using the method by Emtenäs (Scheme 28). 65  
 
 
Scheme 28: Synthesis of thiazoline 84 65 
 
 
The C-H activation reaction was attempted with 84 and phenyl acetylene 
86 as a test reagent but as feared the facile thiazoline was oxidized to the 
thiazole 87 (Scheme 29) as seen by 1H NMR with the peak at around δ 8.2  
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Scheme 29: Coupling of 84 via C-H activation64 
 
With the alkyne attachment to 84 unsuccessful and a supply of this material 
still available a literature search found that work by Popov et al had 
halogenated a benzothiazole 88 (scheme 30) 61     
 
 
Scheme 30: Halogenation of benzothiazole 
 
This method was trailed with thiazoline 84 but again thiazole formation 
was observed within a highly complex mixture, and none of the desired 
product was able to be isolated (scheme 31). 
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Scheme 31: Halogenation of thiazoline 84 
 
 
2.3 Dithioester Sonogashira route to alkyne bridged luciferin 
 
With it clear that any manipulation involving a complete thiazoline will 
result in formation of a thiazole, it was decided that a route was needed 
where thiazoline formation was left until the last step.  At this point in the 
research a new synthetic route to infraluciferin was complete which 
involved a dithioester, and importantly the cyclisation to form the 
thiazoline at the end of the synthesis. Under this premise a further literature 
search was conducted, and work by Thiono et al showed that 89 can 
undergo coupling reactions with alkynes via a Sonogashira reaction to give 
alkynes 90 attached to a dithioester (scheme 32). 66 
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Scheme 32: Thiono et al Sonogashira reaction 
We had by this point demonstrated that dithioesters can undergo 
substitution reactions with serine to give a precursor to a thiazoline 
moiety.67 From 89 a similar procedure to that used for the new route to 
infraluciferin (section 3) could be followed e.g. adding in serine then 
cyclizing with DAST etc. (scheme 33). 
   
 
Scheme 33.  Proposed new route to 55 
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Following the protocols by Thiono et al the dithioester 89 was produced 
and then the coupling of this compound to our previously produced 
benzothiazole 68 bering an alkyne was attempted (scheme 34). 
 
 
 
 
Scheme 34: Sonogashira coupling of 89 and 68 
All attempts to add in our alkyne failed to give any product, only SM and 
some degradation was observed (table 3). 
 
 
Table 3: Sonogashira coupling reaction conditions 
 
Catalyst Eq Base Solvent Temp °C Result 
Pd(PPh3)4/CuI 5-10 % / 
10% 
2,6 lutidine DMF rt SM/Complex 
mixture 
PdCl2(PPh3)2/CuI/PPh3 5-10 % / 
10% 
Et3N DMF rt SM/Complex 
mixture 
Direct addition  n-BuLi THF -78 – 0 °C Degradation/complex 
mixture 
 
2.4 Linear synthesis to alkyne bridged luciferin 
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Having tried several convergent type routes to produce the alkyne bridged 
luciferin it was decided to attempt the synthesis of the analogue with a 
route similar to the original synthesis of infraluciferin.  This would mean 
producing the intermediate 91 (figure 8) which would then be coupled with 
the cysteine derivative 92 and cyclised using the Hendrickson reagent 
(scheme 35) as per the procedure detailed in chapter 3 (scheme 42). 46 
 
 
 
Figure 8: alkyne bridged luciferin intermediate 
 
 
Scheme 35:  Proposed linear route to alkyne bridged luciferin 
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By this stage in the research the new synthetic route to infraluciferin was 
complete, and had shown that the MEM protecting group could be removed 
at the end of the synthesis without affecting the final molecule (scheme 70).  
This successful synthesis would guide us to use this protecting group for 
other routes, and thus we was able to use 93 as our starting point for this 
analogue.  By treating 93 with our Ohira Bestmann reagent 68 we produced 
the alkyne 94 (scheme 36). 
 
 
 
 
 
Scheme 36: synthesis of intermediate 94 
Following standard conditions for the formation of a carboxylic acid using 
n-BuLi as a base and CO2 gave the desired intermediate 95 in a 55 % yield 
(scheme 37). 68 
 
 
 
 
Scheme 37: Carboxylic acid formation 
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The necessary trityl and methyl ester protected amino acid cysteine 92 was 
produced in two steps (scheme 38).69  
 
 
Scheme 38: synthesis of protected cysteine methyl ester 92 
Using the protocols from the original synthesis of infraluciferin to couple 
95 with 92 using BOP (scheme 42) failed to give any product 96 (scheme 
39).46 
 
 
Scheme 39: Peptide coupling via Bop 
 
Another amide coupling reagent (diisopropylcarbodiimide) 97 was used 
which did give the desired product 96 which is purified by column 
chromatography in EtOAc/Hex 1:1 to a sweet smelling waxy yellow solid  
(scheme 40)  
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Scheme 40:  amide coupling of 95 and 92 
 
Unfortunately time constraints only allowed for a few attempts at the 
cyclisation using the Hendrickson reagent, and these failed to give the 
desired compound 98 (scheme 41) 
 
Scheme 41: Cyclisation to thiazoline using the Hendrickson reagent  
 
3 New synthetic route to infra-luciferin 
3.1 Original Synthesis  
 
 
Figure 9: Infra-luciferin 
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Following the successful synthesis of the trans-alkene infraluciferin 54, and 
confirmation that the compound is the furthest red shifted analogue to date, 
we attempted to improve the synthetic route.46 The published synthetic 
route to infraluciferin (scheme 42) began with lithium halogen exchange of 
benzyl protected benzothiazole 99 and subsequent addition of DMF to form 
the aldehyde 100.  A Wittig reaction between the aldehyde 100 and the 
reagent 101 gave the ester 102 containing the desired double bond. The 
ester was converted to the free acid 103 via saponification with NaOH.  
With the double bond in place, the free carboxylic acid underwent an amide 
coupling with trityl protected cysteine methyl ester, using BOP as the 
coupling reagent to give 104, a precursor to the desired thiazoline moiety.  
Cyclisation with OPPh3/Tf2O (Hendrickson reagent) gave the thiazoline 
105 in a reasonable 65% yield.  However the reaction was extremely 
capricious, often failing to give any usable amount of product and would 
not scale up beyond a few tens of milligrams.  The penultimate step of the 
synthesis was deprotection using BBr3 to give 106.  This is a harsh reagent 
and on scale up past 10 – 20 mg the thiazoline can undergo major 
degradation resulting in a drastic loss of material, which at a late stage in 
the synthesis was extremely costly.  The final step is saponification of the 
ester to the free acid, with pig liver esterase to preserve any enantomeric 
excess 46 
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Scheme 42: Original route to infraluciferin 54 
 
The original synthetic route gave an overall yield of around 17 %, however 
because of the problems encountered this meant that at most only 10 –20 
mg were able to be produced from any one batch, thus limiting the material 
available for biological testing. 
It was also hoped that the single enantiomer (D) could be obtained from 
this route by starting with D-cysteine, as this is the natural form of luciferin 
found in the firefly and has been the subject of debate regarding the effect 
S
N
BnO
Br
S
N
BnO
O
H
nBuLi
96%
Ph3P CO2Et
(3 eq)
PhMe 
reflux,16 h
S
N
MeO CO2Et
84%
S
N
BnO CO2H
1M NaOH
iPrOH
92%
80%
S
N
BnO
HN
O
STrt
CO2Me
DMF
BOP
 OPPh3, Tf2O
0 oC to rt
16 h
65 %
S
N
BnO
S
N CO2Me BBr3 (10 eq),
DCM,
 -78 oC to rt
S
N
HO
S
N CO2Me
79 %
S
N
HO
S
N CO2HPLE
Overall yield 17 %
99 100
101
102
103
NH2
MeO
O
STrt
.HCl
101
104
105 106
54
University College London 57 
of the L enantiomer in terms of light emission/inhibition and 
conversion.28,70,71 Unfortunately racemization occurred at the cyclisation 
step with OPPh3/Tf2O (Hendrickson reagent), and therefore if another 
synthetic route could be found then the single enantiomer may also be 
obtained.  
3.2 First attempt at Alternative route to infralucifern 
To circumvent the unreliable cyclisation using the Hendrickson reagent and 
breakdown of the thiazoline ring by BBr3 from the original synthesis, we 
proposed a new route (Scheme 43).  This new route would utilize the 
previously synthesised aldehyde 67 in a Wittig reaction with 107 to form 
the thioamide 108.  Deprotection of the methoxy group prior to the 
formation of the thiazoline ring to give 109 would prevent thiazoline 
degradation, which occurs upon late stage removal of the methyl group 
from the benzothiazole. Conversion of the primary thioamide to a better 
leaving group such as phthaloyl chloride in 110 would allow for a peptide 
coupling with serine as either the ethyl or methyl ester 111 (with the 
alcohol protected if required) to give the penultimate 112.  Deprotection of 
the hydroxyl group if required, followed by conversion to a chloride by 
standard thionyl chloride procedure would allow cyclisation forming the 
thiazoline ring, and simultaneous hydrolysis of the ester to give 54 without 
the use of the Hendrickson reagent (scheme 43). 
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Scheme 43: Proposed new route to infraluciferin 54 
 
The known Witting reagent 107 was synthesized in three steps from 2-
chloroacetamide 113 and triphenylphosphine. The phosphonium salt 114 
produced from this reaction was subjected to Lawesson’s reagent to induce 
thiation of the oxygen to give the thioamide 115.  Finally sodium hydroxide 
was used to convert the crude salt to the Wittig reagent 107 (49% yield, Lit. 
yield72 49% mp 180-185°C, lit mp 182-185°C) (scheme 44). 
 
 
Scheme 44: Synthesis of the Wittig reagent 107 72 
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Treatment of the aldehyde 67 with the Wittig reagent 107 gave the α,β-
unsaturated thioamide 108 in 75 % yield (Scheme 45).  Interestingly the 
ratio of alkenes obtained was 2:1 trans to cis, but on leaving the mixture as 
a solid sitting in the presence of sun light the ratio was altered to more than 
90% of the trans isomer.  This was determined by analysis of the alkene 
protons by 1H NMR; Trans 7.76 (d, J = 15.4 Hz, 1H), δ 7.26 (d, J = 15.4 
Hz, 1H).  Cis δ 6.68 (d, J = 12.7 Hz, 1H), δ 6.61 (d, J = 12.7 Hz, 1H) 
 
 
Scheme 45: Wittig reaction between 67 and 107 
  
The free hydroxyl group on the benzothiazole is required in the final 
compound and previous attempts to de-protect after the formation of the 
thiazoline ring formation have resulted in degradation.  To avoid 
degradation of the thiazoline ring it was decided therefore to proceed with 
unveiling the hydroxyl once alkene formation was complete. 
Demethylation of 108 using boron tribromide gave 109 in 35 % yields with 
approx 30 – 40 % recovered starting material (scheme 46). 31 
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Scheme 46: Demethylation of 108 
 
Brain et al have shown that primary thioamides can be converted in to 
suitable leaving groups for displacement by an incoming amine to give the 
desired thioamide by using phthaloyl chloride 116 (scheme 47) 73 
 
 
Scheme 47: Previous example of thioamide by amine displacement 
 
Phenol 109 was treated with phthaloyl chloride 116 in an attempt to form 
110 (scheme 48), to provide a good leaving group for peptide coupling with 
serine.  However this product was not seen from proton NMR and mass 
spec showed no product with a molecular weight near the 366.41 of the 
desired product, only degraded fragments.   
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Scheme 48: leaving group synthesis 
 
There is also literature president for this reaction where pyridine is used in 
place of potassium carbonate.  This however was also unsuccessful, only 
showing fragmented products by mass spec (table 4). 
Table 4: Leaving group attachment 
 
 
Following the unsuccessful attempts to convert the thioamide 109 to a good 
leaving group, a further literature search revealed direct addition protocols 
for amino-alcohols to thioamides.  In fact under acidic conditions formation 
of the thiazoline group occurred in situ. (Scheme 49)74   
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Scheme 49: Addition of aminoalcohol to thioamide and thiazoline formation 
 
Treatment of 109 with serine methyl ester under the same acidic conditions 
was attempted in order to give the uncyclised precursor 117 (scheme 50). 
 
 
Scheme 50: Direct addition of serine to 109 
 
All attempts were unsuccessful only benzothiazole peaks being discernable 
from the complex NMR spectra.   The alkene and the thioamide portions of 
the starting material were degraded and separation of any compounds from 
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thioamide, allowing the amine to attack the thioamide to give the product 
and ammonia (Scheme 51) 75 
 
Scheme 51: Transamidation using benzoic acid and proposed intermediate 
 
Trials with this route proved unsuccessful with only stating materials 
recovered.  (Scheme 52) 
 
Scheme 52: Transamidation of 109 using benzoic acid  
 
One final attempt was made at transamidation using the boron reagent 
B(OCH2CF3)3 which has been shown by the Sheppard group at UCL to be 
effective for the transamidation of DMF (scheme 53). 76   
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Scheme 53: Transamidation of DMF using B(OCH2CF3)3 
 
Attempts at transamidation using B(OCH2CF3)3 reagent with 109 were 
unsuccessful showing only degraded material (scheme 54).  
 
 
Scheme 54: Transamidation of 109 using B(OCH2CF3)3 
 
 
3.3 Convergent Dithioester route to infra-luciferin 
With attempts at producing infraluciferin 54 from 109 unsuccessful an 
alternative route to 54 was sought.  As the compound 118 is a complete 
half of luciferin and has the aldehyde functional group, a more convergent 
route where by a complete thiazoline moiety with a phosphonate attached 
119 would enable a simple Wittig reaction to produce infraluciferin 
needing only deprotection instantly 120 (scheme 55). 
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Scheme 55: Proposed convergent synthesis via Wittig reaction  
 
 
A literature search reveled that work done by Masson et al and a few others 
had indeed made use of 119 albeit with their R group being alkyl, benzyl 
and not acids or esters.  77 78 66 
A particular example by Masson was the coupling of 121 to simple 
aldehydes where R = H, Et, Ph, Bn, R1 = H and R2 = Me, Ph, i-Pr (scheme 
56) 
 
 
 
Scheme 56: Wittig reaction of 121 with simple aldehydes  
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The use of DBU as a mild base and LiCl as a catalyst is ideal for use with 
our often-facile synthetic intermediate molecules.  The lithium ion 
coordinates to either the nitrogen or sulfur of the thiazoline and the oxygen 
of the phosphonate, making the protons of the CH2 more acidic and easily 
removed via DBU (scheme 57). 77 
 
 
 
Scheme 57: Proposed activation using LiCl  
A further literature found that various amino alcohols had been reacted 
with phosphonodithioacetate 122 and then cyclised via an intramolecular 
Mitsunobu reaction to give the thiazoline Wadsworth Horner Emmons 
reagent 123 R = H, Et, Ph, Bn (scheme 58) 79  
 
 
Scheme 58: Synthesis of thiazoline phosphonate  
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All that is required for a similar route to infraluciferin is to replace the 
amino alcohol with serine methyl or ethyl ester to give 124, cyclise to yield 
the desired thiazoline 125 and perform the Wittig coupling with 118 
(scheme 59). 
 
 
Scheme 59: Proposed route to infra-luciferin via phosphonate intermediate 
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hydrogen sulfide gas was passed through the solution and after an aq. work 
up the final product 122 was obtained. Both reactions were successfully 
carried out on large (5-10g) scale, and without the need for any purification 
(>95 % by H1 NMR) and the whole process could be achieved in two days. 
 
 
Scheme 60: Synthesis of phosphonodithioacetate 122 
Due to the hazards associated with using these gases, and their corrosive 
nature and foul stench, an alternative route was attempted to produce 122 
that avoided using HCl and H2S gas cylinders and the foul stench of 
ethanethiol.  This reaction produced the methyl ester instead of the ethyl 
ester but the product required purification by column chromatography and 
was found to be unstable on silica resulting in degradation, and no pure 
product was isolated (scheme 61) 81 
 
 
Scheme 61: Alternate synthesis of a phosphonodithioacetate 134 
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It was decided that because of the scalability and purity of the product 
produced 122 (scheme 60) this route was the most suitable. 
With multiple grams of pure 122 in hand the next stage was for the 
substitution by serine methyl ester Vazeux et al. had previously described 
the substitution of serine methyl ester on a similar dithioester (scheme 62) 
81 
 
 
 
Scheme 62: Established substitution conditions of serine to dithioester  
 
The reaction with our substrate took 48 h to go to completion as monitored 
by 31P NMR 122 δ 17.14 to give the product 124 δ 21.41 in yields of 95 % 
or greater (scheme 63).  It is worth noting that 124 is extremely reactive 
and has to be kept below 0 °C and used within 48 h or noticeable amounts 
of degradation are observed.  
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Scheme 63: Addition of serine methyl ester 
 
Analysis by 1H NMR showed δ 5.2 (CH from serine) and δ 5.49 (CH2 from 
phosphonate), mass spec gave m/z 314 consistent with the formation of the 
product, which was purified by column chromatography.  This reaction was 
very scalable and the entire amount of product from a batch of >10 g of 122 
could be used whilst maintaining high yields. 
The first option from this point was to cyclise 124 to give the HWE reagent 
with the thiazoline preformed.  Masson et al. had previously attached an 
amino alcohol to 122 and then performed a Mitsunobu type reaction to 
form a thiazoline, this method was attempted and gave 128 in excellent 
yields (Scheme 64).  1H NMR showed a clear shift from δ 4.0 to δ 3.2 for 
the CH2 which originated from serine and the formed the thiazoline ring, a 
mass spec of m/z 296 was consistent with the formation of the thiazoline. 77  
 
Scheme 64: Formation of thiazoline 128 
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This reaction also works on lager scales (>1g) and gave 128 in excellent 
yields (~85 %) after purification by column chromatography. 
With the thiazoline half of infraluciferin attached to a phosphonate the next 
step was to investigate the HWE reaction with the benzothiazole portion of 
luciferin.  The same conditions were used from the Masson paper, which 
employed DBU and lithium chloride as mild reagents to form the double 
bond whilst not affecting the thiazoline ring  (scheme 65). 77  
 
 
Scheme 65: HWE using mild conditions 
 
This reaction failed to give 129 and instead the thiazole 130 was isolated 
from the reaction, the thiazole clearly identified by 1H NMR with the loss 
of the signal at CH2 δ 3.2 and formation of a new signal for the CH of the 
azole at δ 8.21.  The reduced alkene 131 was also formed as a trace product 
< 5 %, 1H NMR showing the two CH2 protons at δ 3.63 and the thiazole 
CH at δ 8.06 (scheme 66). 
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Scheme 66: Unwanted products from DBU/LiCl HWE reaction 
 
As the use of the reversible base DBU proved to be problematic resulting in 
azole formation with our substrate, it was decided that the use of a non-
reversible base such n-BuLi might be more suitable to form the ylide for 
the HWE reaction. The supply of aldehyde 67 was now depleted so 
benzaldehyde 132 was used as a test the aldehyde for the reaction which 
gave the desired alkene in 133 59 % yield (scheme 67). 
 
Scheme 67: HWE using n-BuLi 
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been previously used by Santaniello et al and also Branchini et al for the 
synthesis of luciferin analogues, albeit with the azole instead of the 
thiazoline (scheme 68). 82 Deprotection of the MEM group had been 
induced using neat TFA, and we believed the thiazoline to be stable to acid 
this would be a viable protecting group.  Better still the removal of MEM 
group had been shown by Williams et al to proceed in quantitative yields 
with ZnBr2 (scheme 69).83 84  
 
 
 
Scheme 68: Santaniello et al MEM protection/deprotection 
 
 
 
Scheme 69: Williams et al MEM deprotection via ZnBr2 
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The required benzothiazole aldehyde 93 was prepared in 2 steps starting 
from 134 MEM protection was followed by deprotonation of the most 
acidic proton of the benzothiazole and quenching with DMF.  Aldehyde 93 
was isolated in 77 % yields after column chromatography (scheme 70). 
 
 
Scheme 70: MEM protection and aldehyde formation 
 
With both halves of the molecule complete the HWE reaction utilizing n-
BuLi was attempted (scheme 71). 
 
 
Scheme 71: HWE using n-BuLi and MEM protected aldehyde 
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Given the low yields of the reaction some optimization was carried out by 
altering conditions, but no significant results were observed (table 5).   
 
 
 
 
Table 5: ylide formation using n-BuLi 
 
 
The use of another nonreversible base was then considered and sodium 
hydride was trialed in this reaction (scheme 72). 
 
 
Scheme 72: HWE using NaH and MEM protected aldehyde 
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The use of sodium hydride gave little or no product within a highly 
complex mixture of UV active compounds. 
The literature conditions we were utilizing for the HWE reaction had all 
used thiazolines with either alkyl groups or an alcohol attached, our 
molecule had an ester in this position and this was possibly making the 
thiazoline susceptible to dehydrogenation to give a thiazole.  For this 
reason and with the supply of phosphonate 128 consumed, it was decided 
to perform the HWE reaction with the un-cyclised HWE reagent 124 and 
the aldehyde 93 (Scheme 73).  
 
 
 
Scheme 73: Proposed alternate HWE using un-cyclised phosphonate 124 
 
serine methyl ester HCl
Et3N, DCM rt
122 124
SEt
S
P
O
EtO
OEt NH
S
P
O
EtO
OEt
OH
OMe
O
135
P
O
EtO
OEt
128
N
S
O
OMe
93
N
S
O
OMe
S
N
MEMO
O
H
N
SMEMO
136
HN
S
N
SMEMO
cyclisation
OH
OMe
O
HWE 23%
cyclisation
University College London 77 
For this reaction the original conditions from Masson’s work using 
DBU/LiCl were used (scheme 74).77 
 
 
Scheme 74: HWE with un-cyclised phosphonate 1124 using mild DBU/LiCl 
 
Pleasingly this reaction proceeded to give the product 136 in 60% yield 
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followed as that for conversion of 124 to 128 (scheme 64).77 Unfortunately 
after several attempts this reaction failed to give 135 and only ever resulted 
in producing the thiazole 137 (scheme 75). 
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Scheme 75: Cyclisation to thiazoline using DEAD 
 
 
A literature search for the formation of thiazolines yielded a procedure 
using the reagent DAST.  This method was specifically used by Nicolaou 
to form a thiazoline with an ester attached without the formation of a 
thiazole (scheme 76).85 
 
 
Scheme 76: Nicolaou thiazoline formation 
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These conditions were used with our intermediate 136 (scheme 77) and 
gave excellent results, eventually being conducted on a 500 mg scale to 
give 95 % yields of 135.  
 
 
Scheme 77: Cyclisation to thiazoline using DAST 
 
Not only was this reaction very scalable with consistently high yields but 
the crude product after extracting the aqueous phase with EtOAc was pure 
enough by 1H NMR (>95 % and no thiazole observed by 1H NMR) to need 
no further purification for use in the next step. 
An attempt was made to remove the MEM protecting group, using ZnBr2 
that Williams (scheme 69)83 had used to give quantitative yields (scheme 
78).   
 
 
Scheme 78: ZnBr2 MEM deprotection 
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This reaction failed and gave back only SM and some degraded material; 
presumably the nitrogen or sulfur atoms coordinate to the zinc and inhibit 
the deprotection of the MEM group.  MEM deprotection occurs via 
coordination of zinc to 2 of the oxygen atoms in the MEM chain. 
Another method was used for the deprotection of the MEM group as used 
by Branchini and Santaniello, which was to stir in neat TFA (scheme 79).84 
 
 
Scheme 79: TFA deprotection of MEM 
 
Initially the exact protocols of Branchini and Santaniello (stirring the 
substrate in neat TFA at rt for 3 – 4 h, then add H2O and stirred for 15 min 
and extracted with EtOAc).  This resulted in a 33% yield of material 
isolated, where there was possibly degradation of our benzothiazole, also 
TFA was still present as observed via 19F NMR.  The reaction was 
optimised by stirring in neat TFA at rt for 1 hr then quenched with 
NaHCO3 at 0 °C for 15 min extracted with EtOAc to give 95% of pure 106 
with no trace of TFA or thiazole.  This reaction was reproducible and could 
be scaled to give >350 mg of pure product 106 in consistent yields (~ 95 
%) 
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For the final conversion of ester 112 to the free acid to give infraluciferin 
54 saponification with LiOH was used (scheme 80).   
 
 
Scheme 80: Saponification with LiOH 
 
However on closer examination of the final product there was around 1 – 3 
% contamination with the thiazoleazole 138 observed by 1H NMR signal at 
δ 8.21. 
 
 
Figure 10: infraluciferin Azole contaminant  
 
Unfortunately even 1 % of this compound drastically reduces light 
emission from the luciferase enzyme, as this molecule is believed to inhibit 
the active site and emits no light itself.  The initial reaction called for 2 
equivalents of LiOH and had a reaction time of 30 minutes. All solvents 
were flushed with argon as we were aware that the oxygen can lead to 
dehydrogenation with infraluciferin to give the thiazole.  This however did 
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not prevent the formation of the thiazole.  Re-crystallization from MeOH 
was used to obtain pure infraluciferin, but only around 20 % of the material 
was returned.  Optimization of the LiOH equivalents was carried out to 
obtain pure infra luciferin from the initial saponification by LiOH (table 6) 
 
 
 
 
 
 
 
Table 6: Saponification reaction conditions 
 
 
Eq of LiOH Reaction 
Time min 
Result 
2 30 90 % infra 1 -3% azole 
1.5 30 55 % infra 30 % ester 1 -3% azole 
2 20 50 % infra 30 % ester 1-2 % azole 
2 10 50 % infra 30 % ester 1 % azole 
2 5 50 % infra 30 % ester  
2.5 5 62 % infra 30 % ester 
3 5 77 % infra 20 % ester 
3.5 5 85 % infra 10 % ester 
4.3 5 90 % infra  
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This reaction was scaled up to > 150 mg with consistent yields and without 
formation the thiazole. Over 600 mg of pure infraluciferin was produced 
using these protocols. 
 
4 Convergent Dithioester route to dimethyl-infra-luciferin 
With a successful route to infraluciferin complete it was decided to test the 
new route to synthesise further analogues. It has been shown that by 
replacing the hydroxyl group on the benzothiazole portion of the molecule 
the wave length of light emitted can be altered,  in particular work carried 
out by Miller et al showed that having NH2 on luciferin red-shifted light 
emission by 36 nm, MeNH 52 nm and Me2N 66 nm.86 As the 
dimethylamine appears to red-shift the furthest and having two methyl 
groups avoids the need for protecting groups this analogue was chosen as 
the first analogue to attempt 139.86 
 
 
Figure 11: Dimethylamino infraluciferin 
 
To utilise the synthesis previously developed for infraluciferin the aldehyde 140 first 
needed to be synthesized. 
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Figure 12: Dimethylamino benzothiazole aldehyde 
 
This aldehyde would then be reacted with phosphonate 124 for a HWE 
reaction under the same conditions previously used, followed by 
cyclisation using DAST to give 142 (scheme 81). 
 
 
Scheme 81 Proposed route to 142 
 
Fortunately the desired aldehyde had been previously produced in three 
steps by Ono et al (scheme 82). 87  
 
 
Scheme 82: Three step synthesis of aldehyde 140 
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The first step known as the Bechamp reduction was achieved in an 82% 
yield (lit. 91%).  The second methylation step was low yielding 22% (lit. 
26%) but could be scaled up to multi gram quantities (and the starting 
materials are much cheaper than that of infraluciferin) giving white crystals 
after column chromatography.  The formylation of 143 proceeds with an 82 
% yield after crystallizing from EtOAc (lit. 97%), the literature procedure 
did not purify the material, it was used as the crude product obtained. 
With the desired aldehyde 140 in hand the HWE reaction with 124 was 
attempted (scheme 83). 
 
 
 
Scheme 83: HWE coupling reaction of 140 and 124 
 
Pleasingly this reaction worked and in yields equal to that as the synthesis 
of infraluciferin, 58 % after column chromatography.  This reaction was 
scaled up to > 200 mg of 140 without effecting yields.  
 
The cyclisation of infraluciferin utilized DAST as the reagent to cyclize 
136 to give 135 (scheme 77), this method was again used for the 
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conversion of 141 to 142 (scheme 84).  The first attempts gave low yields 
12 % as opposed to 83 % for infraluciferin (scheme 77). 
 
 
Scheme 84: DAST cyclisation 
 
The original protocols for infraluciferin used 1.2 eq of DAST stirred at -78 
°C for 30 min then worked up immediately.  As this method showed 
incomplete conversion by TLC for the dimethylamino substrate 141, 
optimization was conducted  (table 7). 
Table 7: DAST cyclisation of 141 
CH2Cl2 -78oC
DAST
S
N
N
N
S
O
OMe
142
S
N
N
HN
S
OH
O
OMe
141
53 - 80 %
Eq of DAST Reaction 
Time at – 78 
°C  
Reaction 
Time at  rt 
Result 
1.2 30 min  12 % product + SM 
1.2 30 min 15 min ~20 % product + SM 
2 30 min 15 min ~30 % product + SM 
2 1 h 15 min ~40 % product + SM 
2 2.5 h 15 min ~40 % product + SM 
2 2.5 h O/N ~40 % product + SM 
3 2.5 h 15 min ~50 % product + SM 
4 2.5 h 15 min >80 % product  
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With the ester of our dimethyl amino infraluciferin complete the final 
saponification to the free acid using the protocols developed previously 
were used  (scheme 85). 
 
 
 
Scheme 85: Saponification with LiOH 
 
 
Future Work and conclusions  
5.1 Future Work 
As is the case with any research project of this nature some aspects require 
more time invested.  It was with this project that time constraints meant 
that two main areas needed further investigation.  Firstly the synthesis of 
the alkyne bridged luciferin 32 that was an on going project through out the 
course of the three years, only became as close to completion as it did in 
the final few weeks of the time that I had available.  Therefore I feel that 
with the final linear synthetic route outlined in Scheme 30 warrants further 
investigation, and with a few minor synthetic alteration the analogue could 
be produced. 
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Secondly one of the goals was to produce the single enantiomer of 
infraluciferin 104, some brief work was carried out which utilised the 
successful new route outlined in chapter 3.  However no meaningful data 
was able to be collected with the time and materials available, however 
with an efficient route to racemic infraluciferin now complete this would be 
an ideal starting point with which to attempt to isolate the single 
enantiomer. 
 
 
5.2 Conclusions 
Focusing on the successes form the time spent on this doctoral research, the 
new efficient convergent route to the furthest red shifted luciferin analogue 
infraluciferin has proved to be worthwhile by itself.  With over 600 mg 
produced this has allowed for a large scale parametric in vivo study to be 
under way which would not have been possible via the original route.  This 
has also resulted in two publications 88,89 and a third pending.  Not has this 
route opened up the use of infraluciferin to more research but has already 
allowed for the new analogue dimethylinfraluciferin.  Hopefully the new 
route will be utilised to produce even more analogues. 
During the course of the research several attempts were made to produce 
the alkyne-bridged luciferin 32, finally producing a route with real promise, 
and at the least has eliminated the other more conventional approaches.   
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Experimental 
6.1 General Experimental  
Unless otherwise stated, all reactions were carried out under an atmosphere 
of nitrogen. All glassware was flame dried under a stream of nitrogen 
before use. Cooling to 0 °C was effected using an ice-water bath. Reactions 
were monitored by thin layer chromatography (TLC) using Polygram Sil 
G/UV254 0.25 mm silica gel precoated plastic plates with fluorescent 
indicator. Sheets were visualised using ultraviolet light (254 nm), ninhydrin 
or KMnO4, as appropriate. Flash chromatography was performed using 
Fluorochem silica  
gel 60, 35-70 µ. The liquid phase was analytical grade 40-60 petroleum 
ether (pet. Ether) and ethyl acetate (EtOAc) unless otherwise stated.  
Removal of solvents (in vacuo) was achieved using a Vacuubrand 
diaphragm pump or house vacuum and Büchi rotary evaporators. All NMR 
data was collected using a Bruker AMX 300 MHz, Bruker AVANCE III 
400 MHz, Bruker AVANCE 500 MHz or Bruker AVANCE III 600 MHz. 
Data was manipulated directly using Bruker XwinNMR (version 2.6)  
Mnova (version 9.1.0). Reference values for residual solvents were taken as 
δ = 7.27 (CDCl3) and 2.51 ppm (DMSO-d6) for 1H NMR; δ = 77.16 ppm 
(CDCl3) for 13C NMR. Multiplicities for coupled signals were denoted as: 
s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br. = broad, 
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apt. = apparent and dd = double doublet etc. Coupling constants (J) are 
given in Hz and are uncorrected. Where appropriate, COSY, DEPT, 
2HMBC, HMQC and NOE experiments were carried out to aid assignment.  
Mass spectroscopy data was collected on a Thermo Finnigan Mat900xp 
(EI/CI) VG-70se (FAB) and Waters LCT Premier XE (ES) instruments. 
Infrared data was collected using a Perkin-Elmer 1600 FTIR machine as a 
thin film unless otherwise stated. Elemental analysis was performed on an 
Exeter Analytical Inc. EA440 horizontal load analyser. Melting points are 
uncorrected and were recorded on a Stuart Scientific SMP3 system.  
 
 
 
6.2 Purification of Solvents and Reagents 
Commercial solvents and reagents were used as supplied or purified in 
accordance with standard procedures, as described below. THF, Et2O and 
Toluene were obtained from solvent towers, where the degassed solvent 
was passed through a 7 micron filter under 4 bar pressure. 
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6.3 Experimental Procedures 
6-methoxybenzo[d]thiazole-2-carbaldehyde 67 50 
 
To a solution of 6-methoxy-2-methylbenzothiazole 66 (1.00 g, 5.58 mmol) 
in dioxane (30 mL) was added selenium dioxide (0.620 g, 5.58 mmol) and 
the reaction mixture was brought to reflux (105-110 °C).  The progress of 
the reaction was monitored by TLC and after 4 h at reflux the reaction was 
allowed to cool to room temperature, and left to stir over night.  The 
mixture was filtered through celite and washed with ethyl acetate, then 
concentrated in vacuo to give 1.17 g of orange solid.  Purification by 
column chromatography (100% CHCl3) gave 6-methoxybenzo[d]thiazole-
2-carbaldehyde 67 as yellow crystals mp 120 °C (0.690 g, 64%); 1H NMR 
(500 MHz, CDCl3) δ 10.10 (s, 1H,COH), 8.11 (d, J = 9.1 Hz, 1H, ArH), 
7.39 (d, J = 2.5 Hz, 1H, ArH), 7.21 (dd, J = 9.1, 2.5 Hz, 1H, ArH), 3.93 (s, 
3H, OCH3). NMR data was in agreement with that reported in the 
literature.50 
 
 
Dimethyl (2-oxopropyl)phosphonate 70 52 
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To a solution of potassium iodide (3.00 g, 18.1 mmol) in MeCN (4.5 mL) 
and acetone (3.5 mL) to which chloroacetone 69 (1.73 g, 18.1 mmol) was 
added and stirred at rt for 1 hr. Trimethylphosphite (2.24 g, 18.1 mmol) 
was added dropwise and stirred at rt 16 hrs.  The mixture was then heated 
at 50 0C for 30 min to complete conversion and filtered through celite in 
vacuo to give 3.65 g brownish oil.  Purification by column chromatography 
(100% EtOAc) gave dimethyl (2-oxopropyl) phosphonate 70 as a clear oil 
(1.50 g, 50%, Lit yield 62-70%)  1H NMR (600 MHz, CDCl3) δ 3.74 (d, J = 
11.3 Hz, 6H, POCH3), 3.06 (d, J = 22.8 Hz, 2H, POCH2), 2.28 (s, 3H, 
COCH3). 1H NMR data was in agreement with that reported in the 
literature.52 
 
 
4-acetamidobenzenesulfonyl azide 71 52 
 
To a solution of acetamidobenzenesulfonyl chloride 72(4.00 g, 17.1 mmol) 
in DCM (32 mL), tetrabutylammonium chloride (TBAC) (14 mg, 0.04mL) 
was added.  Sodium azide (NaN3) (1.60 g, 25.7 mmol) was dissolved in 
H2O (8 mL) and added to the reaction flask, the mixture was stirred 
overnight at rt.  The DCM was separated from the aqueous layer and 
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washed with H2O (3 x 10mL), dried (MgSO4) then concentrated in vacuo to 
give 4-acetamidobenzenesulfonyl azide 71 as a white solid (3.00 g, 72 %, 
lit yield 91%).  1H NMR (600 MHz, CDCl3) δ 7.91 (d, J = 8.8 Hz, 2H, 
ArH), 7.78 (d, J = 8.8 Hz, 2H, ArH), 7.57 (s, 1H, NH), 2.26 (s, 1H). 1H 
NMR data was in agreement with that reported in the literature.52 
 
Dimethyl (1-diazo-2-oxopropyl)phosphonate (Ohira Bestmann 
reagent) 65 52 
 
To a solution of dimethyl (2-oxopropyl) phosphonate 70 (0.557 g, 3.35 
mmol) in toluene (3 mL) and cooled to 0 °C, was added sodium hydride 
(NaH) (8 mg, 3.10 mmol) and 4-acetamidobenzenesulfonyl azide 71 (0.74 
g, 3.10 mmol) dissolved in THF (1 mL), the reaction mixture was stirred at 
rt overnight.  The mixture was diluted with hexane (5 mL) and filtered 
through celite, washing with Et2O (10 mL), then concentrated in vacuo to 
give dimethyl (1-diazo-2-oxopropyl)phosphonate 65 as a slightly yellow oil 
(0.668 g, 70 %, lit yield 77%) which could be used without further 
purification. 1H NMR (300 MHz, CDCl3) δ 3.82 (d, J = 11.9 Hz, 6H, 
POCH3), 2.25 (s, 3H, COCH3). 1H NMR data was in agreement with that 
reported in the literature.52 
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2-ethynyl-6-methoxybenzo[d]thiazole 68 51 
 
To a solution of 6-methoxybenzo[d]thiazole-2-carbaldehyde 67 (0.193 g, 
1.00 mmol) in methanol (10 mL) with potassium carbonate (0.276 g, 2.00 
mmol) and stirred for 10 minutes.  Dimethyl (1-diazo-2-oxopropyl) 
phosphonate (Ohira Bestmann reagent) (0.230 g, 1.20 mmol) was dissolved 
in methanol (5 mL) and added to the reaction flask, and the reaction stirred 
for 4 hrs.  Ethyl acetate (10 mL) was used to diluted the reaction mixture 
and 5% sodium bicarbonate/H2O (20 mL) added and extracted with EtOAc 
(3 x 20 mL), the EtOAc fractions were combined and washed with brine 
(30 mL) and dried with MgSO4 then concentrated in vacuo to give 0.200 g 
of brown oil.  Purification by column chromatography (1:1 CHCl3/EtOAc) 
gave 2-ethynyl-6-methoxybenzo[d]thiazole 68 as a tan powder (0.189 g, 
44%); 1H NMR (600 MHz, CDCl3) δ 7.95 (d, J = 9.0 Hz, 1H, ArH), 7.29 
(d, J = 2.5 Hz, 1H, ArH), 7.13 (dd, J = 9.0, 2.5 Hz, 1H, ArH), 3.89 (s, 3H, 
COCH3), 3.56 (s, 1H, CH). 1H NMR data was in agreement with that 
reported in the literature. 
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6-methoxy-2-(phenylethynyl)benzo[d]thiazole 78 
 
To a solution of t etrakis (triphenylphosphine) palladium (Pd(PPh3)4) (14 
mg, 0.012 mmol) in DMF (1 mL) (which was degassed by bubbling 
nitrogen through the solvent for 10 mins) was added iodobenzene 76 (48 
mg, 0.24 mmol).  To this reaction mixture was added 68 (50 mg, 0.26 
mmol) dissolved in DMF (1mL), followed by copper (I) iodide (5 mg, 
0.024 mmol) and lutidine (129 mg, 1.2 mmol).  The reaction mixture was 
stirred at rt 16 hrs and the reaction quenched with H2O (10 mL) and 
extracted with EtOAc (10 mL x3), the combined organic layers were 
washed with brine and dried with MgSO4 then concentrated in vacuo to 
give 0.200 g of brown solid, Purification by column chromatography 
(100% CHCl3) gave 6-methoxy-2-(phenylethynyl)benzo[d]thiazole 78 as a 
yellow powder (0.054 g, 78%); 1H NMR (600 MHz, Chloroform-d) δ 7.96 
(d, J = 8.9 Hz, 1H, ArH), 7.65 – 7.62 (m, 2H, ArH), 7.43 – 7.38 (m, 3H, 
ArH), 7.32 (d, J = 2.3 Hz, 1H,ArH), 7.13 (dd, J = 9.1, 2.5 Hz, 1H, ArH), 
3.91 (s, 3H, OCH3). 13C NMR (151 MHz, CDCl3) δ 158.8 (s), 147.6 (s), 
146.1 (s), 137.1 (s), 132.2 (s), 129.84 (s), 128.7 (s), 124.27 (s), 121.4 (s), 
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116.6 (s), 103.5 (s), 95.3 (s), 82.91 (s), 55.9 (s).  m/z (EI) 220 M+H HRMS 
C16H11NOS calcd. 266.0640, found 266.0645 
 
Ethyl 2-oxothiazolidine-4-carboxylate 74 90  
 
To a solution of cysteine ethyl ester HCl 72 (6.00 g, 32.3 mmol) in H2O (40 
mL) and cooled to 0 °C, NaHCO3 (2.72 g, 32.3) was added in portions over 
30 mins, then K2CO3 was added at a rate that kept the reaction mixture 
below 5 0C.  Triphosgene 73 (4.78 g, 16.14 mmol) was dissolved in THF 
(12 mL) and added via a pressure equalized dropping funnel over 2 hrs, 
then stirred overnight.   THF was removed in vacuo and the aqueous 
solution was extracted with DCM (3x 30 mL) and the combined organic 
fractions washed once with brine, then dried with Na2SO4 and concentrated 
in vacuo to give ethyl 2-oxothiazolidine-4-carboxylate 74 as a yellowish oil 
(3.16 g, 55%) which can be used without further purification 1H NMR (600 
MHz, CDCl3) δ 6.26 (s, br, 1H, NH), 4.43 (t, 1H, COCHNH), 4.27 (q, 2H, 
CH3CH2O), 3.70 (dd, J = 11.3, 8.3 Hz, 1H, CHCH2S), 3.63 (dd, J = 11.3, 
5.1 Hz, 1H, CHCH2S), 1.32 (s, 3H, CH3). 1H NMR data was in agreement 
with that reported in the literature. 
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Ethyl 2-(((trifluoromethyl)sulfonyl)oxy)-4,5-dihydrothiazole-4-
carboxylate 64 91 
 
Neat triflic anhydride (1.82 g, 6.46 mmol) was slowly added o a solution of 
ethyl 2-oxothiazolidine-4-carboxylate 74 (0.942 g, 5.38 mmol) and Et3N 
(1.50 mL, 10.8 mmol) in DCM (20 mL) at -78 0C and stirred for 1 hr.  The 
reaction was quenched with saturated NaHCO3 (20 mL) the organic layer 
separated and washed with brine (10 mL), then dried (Na2SO4) and 
concentrated in vacuo to give 1.27 g of yellowish oil.  Purification by 
column chromatography (3:1 Hexane/EtOAc) gave ethyl 2-
(((trifluoromethyl)sulfonyl)oxy)-4,5-dihydrothiazole-4-carboxylate 64 as a 
slightly yellow oil (0.746 g, 46 %) 1H NMR (600 MHz, CDCl3) δ 5.05 (d, J 
= 7.5 Hz, 1H, COCHNH), 4.39 – 4.32 (m, 2H, COCH2CH3), 3.89 (dd, J = 
11.8, 7.9 Hz, 1H, CHCH2S), 3.57 (dd, J = 11.9, 1.0 Hz, 1H, CHCH2S), 1.34 
(t, J = 7.2 Hz, 3H, CH3). 1H NMR data was in agreement with that reported 
in the literature. 
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Ethyl 4, 5-dihydrothiazole-4-carboxylate 84 65 
 
Neat Et3N (1.25 mL, 9 mmol) was added drop wise to a solution of cysteine 
ethyl ester HCl 72 (2.01 g, 10.00 mmol) in 1,2 dichloroethane (DCE) (15 
mL) at 0 °C, and stirred for 10 mins.  To the reaction flask equipped with a 
soxhlet extractor filled with 4 A molecular sieves was added 
triethylorthoformate (2.22 g, 15 mmol) and DCE (15 mL) and the mixture 
refluxed at 145°C for 2 hrs.  A catalytic amount of p-toluenesulfonic acid 
was then added reflux continued for 18 hrs.  The mixture was then cooled 
to rt, toluene (5 mL) added and the mixture cooled to -15°C.  The 
precipitate was then filtered and solvent concentrated in vacuo to give ethyl 
4, 5-dihydrothiazole-4-carboxylate 84 (1.59 g, 100%) as a brown oil.  1H 
NMR (300 MHz, CDCl3) δ 8.03 (s, 1H), 5.08 (t, J = 7.5 Hz, 1H, 
COCHNH), 4.26 (q, J = 1.2 Hz, 2H, COCH2CH3), 3.50 (m, 2H, CHCH2S), 
1.33 (t, 3H, CH3). 1H NMR data was in agreement with that reported in the 
literature. 
 
Propiolamide 61 48 
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Liquid ammonia (approx. 14 mL, 0.59 mmol) was added to a reaction flask 
which was cool to -78 °C and fitted with a dry ice condenser.  
Methylpropiolate 60 (4.13 mL, 50mmol) was added drop wise and the 
reaction mixture and allowed to stir at -78°C for 2 hrs.  The dry ice 
condenser was removed and the reaction flask was placed in a water bath 
and allowed to warm to rt whilst the excess NH3 evaporated.  Et2O (30 mL) 
was added then the solution filtered and concentrated in vacuo.  
Recrystallization from DCM (50 mL) gave propiolamide 61 as white 
crystals (2.06 g, 60 %). 1H NMR (500 MHz, CD3CN) δ 6.71 (s, 1H, NH2), 
6.26 (s, 1H, NH2), 3.26 – 3.19 (m, 1H, CH).  1H NMR data was in 
agreement with that reported in the literature. 
 
 
 
Propiolonitrile 59 92 
 
Into a pestle and mortar was ground propiolamide 61 (1.00 g, 14.50 mmol) 
with sand (approx. 1.00g) and phosphorous pentoxide (3.00 g, 21.75 mmol) 
until a thick paste was formed.  This mixture was transferred to a reaction 
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flask fitted with vacuum distillation apparatus fitted and the flask heated to 
130 0C under vacuum (approx. 30-40 mbar) and the distillate allowed to 
collect in a receiving flask cooled to -78 °C over 2 hrs to give 
propiolonitrile 59 as a clear oil (0.400 g, 54%).  No further purification was 
needed. 1H NMR (500 MHz, D2O) δ 4.70 (s, 1H).  1H NMR data was in 
agreement with that reported in the literature. 
 
 
(2-amino-2-oxoethyl) triphenylphosphonium chloride 114 72 
  
A solution of 2-chloroacetamide 113 (2.00g, 21.40 mmol) and 
triphenylphosphine in acetonitrile MeCN (10 mL) was heated to 80 °C 
overnight.  The reaction mixture was cooled to rt and the solids broken up, 
TBME (10 mL) added and the slurry was filtered and was with TBME(10 
mL) to obtain (2-amino-2-oxoethyl) triphenylphosphonium chloride 114 as 
a white solid  mp 180-185 °C (Lit mp 182-185 °C) which was dried in 
vacuo (7.1 g, 93 %).  1H NMR (300 MHz, CDCl3) δ 9.83 (s, 1H, NH2), 7.78 
(m, 15H, ArH), 5.57 (s, 1H, NH2), 5.09 (d, J = 14.3 Hz, 2H, PCH2CO). All 
data was in agreement with the literature. 72 
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(2-amino-2-thioxoethyl) triphenylphosphonium chloride 115 72 
 
To a solution of (2-amino-2-oxoethyl) triphenylphosphonium chloride 114 
(7.14 g, 20 mmol) in toluene (75 mL) was added Lawessons reagent (8.10 
g, 20 mmol).  The reaction mixture was heated to 175 °C for 4 hrs and the 
left to stir at rt overnight.  The toluene was decanted off and the residue 
recrystallized from acetone twice, heating to 45 0C each time, and then 
recrystallized from EtOH (45 mL) at 45 0C to yield (2-amino-2-
thioxoethyl) triphenylphosphonium chloride 115 as a white solid mp 270-
275 °C (Lit mp 273-275 °C) (4.70 g, 64%).  1H NMR (500 MHz, DMSO) δ 
7.72 – 7.45 (m, 15H, ArH), 3.81 (d, J = 28.2 Hz, 2H, PCH2CO). All data 
was in agreement with the literature. 72 
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2-(triphenyl-λ5-phosphanylidene)ethanethioamide 107 72 
 
To a solution of (2-amino-2-thioxoethyl) triphenylphosphonium chloride 
115 (4.562 g, 12.27 mmol) in EtOH (40 mL), NaOH (0.58 g, 14.72 mmol) 
in H2O (25 mL) was added and stirred for 15 min then the reaction flask 
was place in a freezer for 3hrs, the mixture was filtered and washed with 
cold EtOH to yield 2-(triphenyl-λ5-phosphanylidene)ethanethioamide 114 
as an off white solid mp 230-235 °C (Lit mp 232-235 °C) (3.27 g, 80%).  
1H NMR (300 MHz, DMSO) δ 7.75 – 7.44 (m, 15H, ArH), 6.60 (s, 2H, 
NH2), 3.82 (d, J = 28.2 Hz, 1H, PPh3CHCS). All data was in agreement 
with the literature. 72 
 
(E)-3-(6-methoxybenzo[d]thiazol-2-yl)prop-2-enethioamide 108 
 
A solution of 6-methoxybenzo[d]thiazole-2-carbaldehyde 67 (0.149 g, 0.77 
mmol) and 2-(triphenyl-λ5-phosphanylidene)ethanethioamide 107 (0.258 g, 
0.77 mmol) in DCM (10 mL) were stirred at rt overnight.  The reaction 
mixture were concentrated in vacuo to give 0.370 g of dark red solid which 
shows approx. a 50/50 ratio of E:Z isomers from the crude 1H NMR, if this 
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crude solid is left to sand in the presence of sunlight the ratio appears to 
covert to >95% of the desired E isomer.  Purification by column 
chromatography (2:1 hexane/EtOAc) gave (E)-3-(6-
methoxybenzo[d]thiazol-2-yl)prop-2-enethioamide 108 as a red solid  
(0.146 g, 75 %) mp 170-175 °C.  1H NMR (500 MHz, DMSO) δ 9.68 (d, J 
= 16.39 Hz, 2H, NH2), 7.93 (t, J = 10.2 Hz, 1H, ArH), 7.76 (d, J = 15.4 Hz, 
1H, CHCHNCS), 7.71 (d, J = 2.5 Hz, 1H, ArH), 7.26 (d, J = 15.4 Hz, 1H, 
NCSCHCH), 7.14 (m, 1H. ArH), 3.84 (s, 3H, OCH3). 13C NMR (151 MHz, 
CDCl3) δ 160.1 (s, SCNH2), 157.9 (s, NCS), 147.9 (ArCOCH3), 146.4 (s, 
ArCN), 137.1 (s, ArCS), 133.4 (s, CH), 133.3 (s, CH), 124.0 (ArC), 116.7 
(ArC), 104.7 (ArC), 55.8 (s, OCH3).  m/z (EI) 220 M+H HRMS 
C11H12N2OS2 calcd. 251.0313, found 251.0310 
 
(E)-3-(6-hydroxybenzo[d]thiazol-2-yl) prop-2-enethioamide 109 
 
 
To a solution of (E)-3-(6-methoxybenzo[d]thiazol-2-yl)prop-2-
enethioamide 108 (0.100 g, 0.400 mmol) in DCM (5 mL) and cooled to -78 
°C was added boron tribromide (BBr3) as a 1 M solution in DCM (1.2 mL, 
1.2 mmol) and the reaction allowed to warm to rt overnight. The reaction 
University College London 104 
was quenched with 5% NaHCO3 and then extracted with EtOAc x 3 (10 
mL), the combined organic fractions were washed with brine and dried 
with MgSO4, then concentrated in vacuo to give 0.94 g of brown solid.  
Purification by column chromatography (1:1 hexane/EtOAc) gave (E)-3-(6-
hydroxybenzo[d]thiazol-2-yl)prop-2-enethioamide 109 (0.030 g, 32 %) as a 
tan solid. 1H NMR (600 MHz, DMSO) δ 9.69 (d, J = 189.3 Hz, 2H, NH2), 
7.85 (d, J = 8.8 Hz, 1H, ArH), 7.75 (d, J = 15.4 Hz, 1H, CHCHNCS), 7.41 
(d, J = 2.4 Hz, 1H, ArH), 7.21 (d, J = 15.4 Hz, 1H, NCSCHCH), 7.01 (dd, 
J = 8.8, 2.4 Hz, 1H, ArH). 
 
 
Diethylphosphono thioimido acetate hydrochloride 127 80 
 
To a solution of diethylcyanomethyl phosphonate 126 (5.00 g, 28.23 mmol) 
in Et2O (25 mL) cooled to 0°C was added ethanethiol (5.26 g, 84.68 mmol).   
HCl gas was passed through the reaction mixture for approx. 3.5 hrs 
keeping the reaction flask at 0°C.  The reaction was monitored by 31P NMR 
showing a peak at δ 15.64 for the product. Once conversion was complete 
as seen by 31P NMR the contents were concentrated in vacuo to give 127 
University College London 105 
6.20 g of yellow viscous oil, this product cannot be purified and is used in 
the next reaction as is. 
1H NMR (300 MHz, CDCl3) δ 4.32 – 4.18 (m, 4H, OCH2CH3), 3.70 (d, J = 
22.5 Hz, 2H, PCH2), 3.57 – 3.46 (m, 1H, CH2CH3), 1.45 (t, J = 7.4 Hz, 3H, 
CH2CH3 ), 1.37 (t, J = 7.1 Hz, 6H, OCH2CH3).  All data was in agreement 
with the literature.  1H NMR all data was in agreement with the literature. 
 
ethyl 2-(diethoxyphosphoryl)ethanedithioate 122 80 
 
To a reaction flask containing 127 (6.20 g, 22.5 mmol) and cooled to 0°C 
was added pyridine (15 mL).  Whilst keeping the reaction flask at 0°C 
hydrogen sulfide gas was passed through the solution, there was observed 
an immediate colour change to vivid orange and the stream of gas was 
continued for approx. 2 hours.  Completion of the reaction was confirmed 
by 31P NMR showing a peak at δ 17.94 for the product.  Ice cold H2O (5 
mL) was added and the mixture stirred for 5 minutes.  HCl/H2O 3:1 (20 
mL) was added and the aqueous phase was extracted with Et2O (3 x 20 mL) 
and the organic phase washed once with HCl/H2O 3:1 (20 mL) dried with 
MgSO4 and concentrated in vacuo to give 122 4.3 g of orange oil 
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1H NMR (300 MHz, CDCl3) δ 4.16 (dq, J = 14.2, 7.1 Hz, 4H), 3.80 (d, J = 
22.7 Hz, 2H), 3.23 (q, J = 7.4 Hz, 2H), 1.34 (m, 9H).  1H NMR data was in 
agreement with the literature. 
 
Methyl 2-(2-(diethoxyphosphoryl)ethanethioamido)-3-
hydroxypropanoate 124 
 
To a solution serine methyl ester in DCM (50 mL) neat Et3N (0.61 mL 4.41 
mmol) was added with stirring until completely dissolved.  A solution of 
Ethyl 2-(diethoxyphosphoryl)ethanedithioate 122 (1.03 g, 4.01 mmol) in 
DCM (10 mL) was added drop wise to the reaction flask.  The reaction was 
stirred at rt for 2 days until 31P NMR showed complete conversion to the 
product.  The reaction mixture was concentrated in vacuo to give yellowish 
oil, which when dissolved in EtOAc precipitated excess serine methyl ester 
formed as a white solid that was filtered off and the mother liquor purified 
by column chromatography (100 % EtOAc - 5% MeOH – 10% MeOH) to 
give methyl 2-(2-(diethoxyphosphoryl)ethanethioamido)-3-
hydroxypropanoate 124 (0.70 g, 56%)  as a yellow oil.  
1H NMR (300 MHz, CDCl3) δ 4.17 (m, 5H, OCH2 + CH2OH), 4.00 (dd, J = 
11.8, 2.8 Hz, 1H, CH2OH), 3.82 (s, 1H, OCH3), 3.49 (m, 2H, PCH2), 1.35 
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(m, 6H, CH2CH3).  13C NMR (151 MHz, CDCl3) δ 63.25 (d, J = 140 Hz, 
OCH2CH3), 61.39 (s, CH2OH), 60.81 (s, NHCH), 52.94 (s, OCH3), 45.10 
(d, J = 127.1 Hz, PCH2), 16.47 (s, CH2CH3).  IR νmax (thin film) 3310 – 
3243, 2982, 1741, 1512, 1225, 1010.  m/z (EI) HRMS C14H21NOPS2 
calcd.314.0802, found 314.0803 
 
methyl 2-((diethoxyphosphoryl)methyl)-4,5-dihydrothiazole-4-
carboxylate 128 
 
 
A solution of methyl 2-(2-(diethoxyphosphoryl)ethanethioamido)-3-
hydroxypropanoate 124 (1.46 g, 4.66 mmol) in THF (100 mL) was treat 
with triphenylphosphine (2.20 g, 8.40 mmol).  After stirring a rt for 5 min 
neat DEAD (1.32 mL, 8.40 mmol) was added dropwise.  After stirring at rt 
for 4 hrs the solution was concentrated in vacuo. Purification was archived 
by flash chromatography (5% MeOH/EtOAc) to give 128 (1.38 g, 85 %) as 
a yellowish oil 
1H NMR (300 MHz, CDCl3) δ 5.08 (dd, J = 15.1, 9.4 Hz, 1H, CHCH2), 
4.25 – 4.03 (m, 4H, CH3CH2O), 3.80 (s, 3H, CH3O), 3.71 – 3.50 (m, 2H, 
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SCH2CH), 3.31 – 3.10 (m, 2H, CH2P), 1.33 (t, J = 7.1 Hz, 6H, CH3CH2O).  
13C NMR (151 MHz, CDCl3) δ 171.10 (s, CO), 165.67 (s, SCN), 77.75 (s, 
CHCH2), 62.90 (t, J = 6.0 Hz, POCH2CH3), 52.93 (s, CH3O), 36.54 (s, 
CH2CH), 33.46 (d, J = 137.7 Hz, CH2P), 16.49 (d, J = 4.4 Hz, CH3CH2). IR 
νmax (thin film) 2980, 1742, 1255, 1023.  m/z (EI) 220 M+ H HRMS 
(C10H18NO5PS+H) calcd. 296.0721. found 296.0719     
     
6-((2-methoxyethoxy)methoxy)benzo[d]thiazole 134a 84 
 
 
A solution of 134 (1 g, 6.60 mmol) in THF (80 mL) was treated cooled to 0 
°C and NaH (316 mg, 13.20 mmol) added in portions.  The reaction 
mixture was stirred at rt for 1 h then cooled to 0 °C and 2-
methoxyethoxymethyl.Cl added drop wise and stirred at rt over night.  The 
reaction mixture was quenched with 5% KCO3 in H2O (160 mL) and 
extracted with EtOAc (80 mL x3) and the organic fractions were combined 
and washed with brine and dried with MgSO4 filtered and concentrated. 
Purification was achieved by flash chromatography (1:1 EtOAc/Hex) to 
give 134a (833 mg, 53 %) as orange oil 
S
N
MEMO
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1H NMR (300 MHz, CDCl3) δ 8.86 (s, 1H, CHNCS), 8.02 (d, J = 8.9 Hz 
1H, CHCHCO), 7.65 (s, 1H, CHCO), 7.22 (dd, J = 8.9 Hz, 2.4Hz 1H, 
CHAr), 5.34 (s, 2H, OCHO), 3.86 (dd, J = 5.6 Hz, 3.7 Hz 2H, 2H, 
CH2CH2O), 3.57 (dd, J = 5.5 Hz, 3.7 Hz 2H, OCH2CH2), 3.37 (s, 3H, 
CH3O). 1H NMR data was in agreement with the literature 
 
 
6-((2-methoxyethoxy)methoxy)benzo[d]thiazole-2-carbaldehyde 93 84 
 
A solution of n-BuLi  (3.83 mmol) in THF (20 mL) was cooled to -78 °C 
and a solution of 134a (833 mg, 3.48 mmol) in THF (5 mL) was added 
drop wise and the mixture warmed to -50 °C for 1 h.  The reaction mixture 
was cooled to -78 °C and DMF (1.08 mL, 13.92 mmol) was added drop 
wise and the reaction was stirred at -78 °C for 2 h.  The reaction was 
quenched saturated NaHCO3 (50 mL) and extracted with EtOAc (50 mL x 
3).  The organic phase dried with MgSO4 and concentrated in vacuo. 
Purification was achieved by flash chromatography (2:1-1:1 EtOAc/Hex) 
to give 93 (672 mg, 72 %) as an orange oil 
1H NMR (300 MHz, CDCl3) δ 10.11 (s, 1H, CHCO), 8.12 (d, J = 9 Hz 1H, 
CHCHCO), 7.67 (s, 1H, CHCO), 7.31 (dd, J = 9 Hz, 2.4Hz 1H, CHAr), 
S
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5.38 (s, 2H, OCHO), 3.87 (m, 2H, 2H, CH2CH2O), 3.58 (m, 2H, 
OCH2CH2), 3.38 (s, 3H, CH3O). 1H NMR data was in agreement with the 
literature 
 
 
2-ethynyl-6-((2-methoxyethoxy)methoxy)benzo[d]thiazole 94 
 
 To a solution of 93 (742 mg, 2.78 mmol) in methanol (25 mL) with 
potassium carbonate (768 mg, 5.56 mmol) and stirred for 10 minutes.  
Dimethyl (1-diazo-2-oxopropyl) phosphonate 68 (Ohira Bestmann reagent) 
(640 mg, 3.33 mmol) was dissolved in methanol (5 mL) and added to the 
reaction flask, and the reaction stirred for 4 hrs.  Ethyl acetate (20 mL) was 
used to diluted the reaction mixture and 5% sodium bicarbonate/H2O (40 
mL) added and extracted with EtOAc (3 x 40 mL), the EtOAc fractions 
were combined washed with brine and dried with MgSO4 then concentrated 
in vacuo.  Purification by column chromatography (1.5:1 Hex/EtOAc) gave 
94 as a orange waxy solid (387 mg, 60%) 
1H NMR (300 MHz, CDCl3) δ 7.96 (d, J = 8.8 Hz 1H, CHCHCO), 7.56 (s, 
1H, CHCO), 7.23 (dd, J = 9 Hz, 2.4Hz 1H, CHAr), 5.35 (s, 2H, OCHO), 
3.86 (m, 2H, 2H, CH2CH2O), 3.58 (m, 2H, OCH2CH2), 3.57 (s, 1H, CHC),  
S
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3.38 (s, 3H, CH3O).  13C NMR (151 MHz, CDCl3) δ 156.57 (1C), 148.00 
(1C), 145.60 (1C), 136.69 (1C), 124.54 (1C, CHAr), 118.01 (1C, CHAr) 
106.91 (1C, CHAr), 94.00 (1C, CH2), 83.59 (1C), 71.66 (1C, CH2), 68.019 
(1C, CH2), 59.20 m/z (EI) 220 M+ HRMS C13H13NO3Ss calcd. 264.0694, 
found 264.0702 
3-(6-((2-methoxyethoxy)methoxy)benzo[d]thiazol-2-yl)propiolic acid 95 
 
 
A solution of 94 (369 mg, 1.58 mmol) in THF (6 mL) was cooled to -78 °C 
and n-BuLi  (1.74 mmol) was added drop wise then left to stir for 30 min.  
A stream of CO2 was passed through CaCl and bubbled through the 
reaction mixture for 30 min.  The reaction was warmed to rt and then made 
acidic (~pH 3) with 2M HCl then extracted with Et2O (10 mL x 3).  The 
combined organic fractions were made basic with 5% Na2CO3/H2O 
solution and extracted with H2O (10 mL x 3).  The combined aqueous 
fractions were again acidified and extracted with Et2O (10 mL x 3) washed 
with brine and dried with NaSO4 filtered and concentrated in vacuo to give 
95 (169 mg, 39 %) as an off  white solid mp 71-76 °C 
1H NMR (300 MHz, CDCl3) δ 8.07 (d, J = 9 Hz 1H, CHCHCO), 7.56 (s, 
1H, CHCO), 7.28 (m, 1H, CHAr), 5.36 (s, 2H, OCHO), 3.88 (m, 2H, 2H, 
S
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CH2CH2O), 3.62 (m, 2H, OCH2CH2), 3.40 (s, 3H, CH3O).  13C NMR (151 
MHz, CDCl3) δ 157.34 (1C), 153.87 (1C), 147.74 (1C), 143.50 (1C), 
137.46 (1C), 125.00 (1C CHAr), 118.98 (1C CHAr), 106.71 (1C CHAr), 
93.99 (1C CH2), 84.86 (1C), 78.50 (1C), 71.71 (1C CH2), 68.00 (1C CH2), 
59.09 (1C CH3) m/z (EI) 220 HRMS C14H13NO5Ss calcd. 308.0593, found 
308.0595 
 
ethyl carbonochloridodithioate 89  
 
A solution of thiophosgene  (6.02g, 52.4 mmol) in benzene (10 mL) was 
cooled to 0 °C and ethanethiol (3.88 mL, 52.4 mmol) in benzene (7 mL) 
was added drop wise.  The reaction mixture was stirred at 0 °C over night 
and then concentrated in vacuo.  .  Purification was achieved by fractional 
distillation to give 89 (485 mg, 60 %) as red oil. 
1H NMR (300 MHz, CDCl3) δ 3.20 (q, J = 7.1 Hz 1H, CH2), 1.37 (t, 7.4, 
CH3) 1H NMR data was in agreement with the literature 
 
S-tritylcysteine 92 46 
Cl SEt
S
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A solution of DL-cysteine. HCl (600 mg, 3.8 mmol) in DMF (3 mL) was 
treated with tritylmethyl chloride (1.62g, 5.81 mmol) and stirred at rt for 2 
days.  To the reaction flask was added 10 % NaOAc/H2O (25 mL) which 
produced a white precipitate that was filtered off and washed with H2O.  
The material obtained was dissolved in acetone and heated to 50 °C for 1 h 
then cooled to rt, filtered and rinsed with acetone then Et2O and dried in 
vacuo to give 92 (870 mg, 65 % lit 89%) as a white solid 
1H NMR (300 MHz, DMSO) δ 7.22 (m, 15H Ar), 2.91 (m, 1H CH), 2.58 
(dd, J= 4.4 Hz, 12 Hz, 1H CH2) 2.49(dd 9 Hz, 12Hz, 1H CH2) mp 190-195 
°C (lit 195°C)  1H NMR data was in agreement with the literature 
 
methyl S-tritylcysteinate 92a 46 
 
A solution of 92  (870 mg, 2.47 mmol) in MeOH (18 mL) was cooled to 0 
°C and thionylchloride (1.35 mL, 18.57 mmol) was added drop wise.  The 
reaction mixture was warmed to rt then concentrated in vacuo to give 90a 
(910 mg, 89 % lit 97%) as a white solid 
HO
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1H NMR (300 MHz, DMSO) δ 7.27-7.39 (m, 15 H Ar), 3.85 (dd, J= 6 Hz, 
6 Hz 1H CH), 3.70 (s, 3H, CO2CH3) 2.58 (m, 2H CH2) mp 73-76 °C (lit 
78°C) 1H NMR data was in agreement with the literature 
 
methyl N-(3-(6-((2-methoxyethoxy)methoxy)benzo[d]thiazol-2-
yl)propioloyl)-S-tritylcysteinate 96 
 
A solution of 95 (176 mg, 0.429 mmol) in DCM (8 mL) was treated with 
DIPEA (75 µL, 0.429 mmol).  To the reaction mixture was added 92a and 
the solution cooled to 0 °C, then diisopropylcarbonimide (64 µL, 0.409 
mmol) was added and left at rt over night.  The reaction was quenched with 
saturated NH4Cl (4 mL) and extracted with DCM dried with NaSO4 filtered 
and concentrated in vacuo.  Purification was achieved by flash 
chromatography (1:1 EtOAc/Hex) to give 96 (54 mg, 27 %) as a yellow 
waxy solid 
1H NMR (600 MHz, CDCl3) δ 8.07 (d, J = 9 Hz 1H, CHCHCO), 7.56 (s, 
1H, CHCO), 7.28 (m, 1H, CHAr), 5.36 (s, 2H, OCHO), 3.88 (m, 2H, 2H, 
CH2CH2O), 3.62 (m, 2H, OCH2CH2), 3.40 (s, 3H, CH3O).  13C NMR (151 
MHz, CDCl3) δ 168.89 (1C), 157.06 (1C), 151.31 (1C), 148.25 (1C),  
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144.23 (1C), 143.23 (1C), 137.44 (1C), 129.59 (6 C Trt), 128.26 (6 C Trt), 
127.18 (3 C Trt), 125.04 (1 C Ar), 118.92 (1 C Ar), 93.96 (1 C CH2), 71.65 
(1 C CH2), 68.08 (1 C CH2), 60.64 (1 C), 59.21 (1C CH3), 53.08 (1C CH3), 
51.65 (1C CH), 33.50 (1C CH2), 29.83 (1C), 21.21 (1C), 20.30 (1C), 19.86 
(1C), 14.33 (1C) m/z (EI) 220 M+ H HRMS C37H34N2O6S2 calcd. 677.1937, 
found 677.1873					 
 
methyl-(E)-(3-(6-((2-methoxyethoxy)methoxy)benzo[d]thiazol-2-
yl)prop-2-enethioyl)serinate 136 
 
A solution 93 methyl 2-(2-(diethoxyphosphoryl)ethanethioamido)-3-
hydroxypropanoate (274 mg, 0.874 mmol) in MeCN (4mL) was treated 
with  DBU (146 mg, 0.961 mmol) and LiCl (41 mg, 0.961 mmol).  After 
stirring at rt for 5 min a solution of 124 6-(β-Methoxyethoxymethyl ether)-
2-formylbenzothiazole in MeCN (4 mL) was added dropwise and stirred as 
rt for 3.5 hrs.  The solution was filtered and concentrated in vacuo.  
Purification was achieved by flash chromatography (75 % EtOAc/Hex) to 
give 136 (188 mg, 50 %) as an orange oil 
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1H NMR (600 MHz, CDCl3) δ 8.95 (br. s, 1H, CH2OH) 8.02 (d, J = 9.0 Hz, 
1H, CH Ar), 7.95 ( d, J = 15.1 Hz, 1H, CHCHCS ), 7.60 ( d, J = 7.25 Hz, 
1H, CH Ar), 7.45 (d, J = 15.1 Hz, 1H, SNCCHCH), 7.25 ( d, J = 2.5 Hz, 
1H, CH Ar ), 5.39 (m, 1H, CH2CHNH), 5.36 (s, 2H,OCH2O), 4.2 (dd,  J = 
11.7, 3.3 Hz,  2H, CH2OH),  3.86 (m, 2H, CH3OCH2), 3.85 (s, 3H, 
COOCH3), 3.58 (m, 2H, CH2CH2O), 3.38 (s, 3H, CH3O). 13C NMR (151 
MHz, CDCl3) δ 192.83 (1C), 170.01 (1C), 163.02 (1C), 156.84 (1C), 
135.56 (1C), 134.99(1C, CH), 131.04 (1C, CH), 123.26 (1C, CHAr), 
119.13 (1C, CHAr), 107.44 (1C), 94.00 (1C), 77.3 (1C CH), 71.63(1C, 
CH2), 68.15(1C, CH2), 62.07(1C, CH2), 60.49(1C, CH), 59.21 (1C, CH3), 
53.17 (1C, CH3), 14.32(1C). IR νmax (thin film) 3100-3500, 2925, 1740, 
1597, 1194, 1077, 991, 822, 732.  m/z (EI) 220 M+ H HRMS 
C36H234N2O6S2 calcd. 427.0998, found 427.0999					 
	
methyl (E)-2-(2-(6-((2-methoxyethoxy)methoxy)benzo[d]thiazol-2-
yl)vinyl)-4,5-dihydrothiazole-4-carboxylate 135 
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A solution of 136 (230 mg, 0.54 mmol) in DCM (3 mL) cooled to -78 °C 
was treated with DAST (85 µL 0.64 mmol).  After stirring at -78 °C for 30 
min the reaction was quenched with saturated aqueous NH4Cl solution (3.5 
mL).  The layers were separated and the aqueous layer was re-extracted 
with DCM (2 × 10 mL). The combined organic layers were washed with 
brine (30 mL), dried Na2SO4, and concentrated.  Purification was achieved 
by flash chromatography (75 % EtOAc/Hex) to give 135 (185 mg, 83 %) as 
an orange waxy solid.  
1H NMR (600 MHz, CDCl3) δ 7.93 (d, J = 9.0 Hz, 1H, CH Ar), 7.57 (d, J = 
2.4 Hz, 1H,  CH Ar), 7.41 (d, J = 16.2 Hz, 1H,  NSCCHCH), 7.33 (d, J = 
16.2 Hz, 1H, CHCHCNS), 7.20 (dd, J = 9.0, 2.46 Hz, 1H, CH Ar), 5.34 (s, 
2H, OCH2O), 5.25 (t, J = 9.3 Hz, 1H, NCHCH2), 3.88 – 3.82 (m, 5H, 
COOCH3, CH3OCH2), 3.73 – 3.60 (m, 2H, SCH2CH), 3.57 (m, 2H, 
CH2CH2O), 3.38 (s, 1H, CH3O). 
13C NMR (151 MHz, CDCl3) δ 170.95(1C), 169.33(1C), 162.61(1C), 
156.37(1C), 149.24(1C), 136.49(1C), 135.04(1C,CH), 129.27(1C, CH), 
124.51(1C. CHAr), 117.77(1C, CHAr), 107.44(1C, CHAr), 93.99 (1C, 
CH2), 78.14 (1C, CH), 71.66 (1C, CH2), 68.01 (1C, CH2), 59.20 (1C, CH3), 
53.13(1C, CH3), 35.07(1C, CH2). IR νmax (thin film) 2900, 1737, 1597, 
1452, 1199, 1102, 991 m/z (EI) 220 M+ H HRMS C18H20N2O5S2 calcd. 
409.0892, found 409.0894						
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methyl-(E)-2-(2-(6-hydroxybenzo[d]thiazol-2-yl)vinyl)-4,5-
dihydrothiazole-4-carboxylate 106 46 
 
	
	
A solution of 135 (440 mg, 0.198 mmol) in neat TFA (14 mL) was stirred 
at rt for 1 h.  The reaction mixture was cooled to 0 °C and saturated 
NaHCO3 (200 mL) was added until a pH of 7-8 was attained.  Extracted 
with EtOAc (3 x 50 mL) and the combined organic fractions were washed 
with brine, filtered and concentrated to give 106 as a yellowish solid (298 
mg, 95 %). 
1H NMR (600 MHz, MeOD) δ 7.82 (d, J = 8.9 Hz, 1H, CHAr), 7.40 (d, J = 
16.1 Hz, 1H, CHCH), 7.29 (d, J = 2.5 Hz, 1H, CHAr), 7.29 (d, J = 16.1 Hz, 
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1H,CHCH), 7.03 (d, J = 8.9Hz, 1H, CHAr), 5.33 (t, J = 9.0 Hz, 1H), 3.76 – 
3.66 (m, 2H, SCH2). )  1H NMR data was in agreement with the literature 
 
 
 
 
(E)-2-(2-(6-hydroxybenzo[d]thiazol-2-yl)vinyl)-4,5-dihydrothiazole-4-
carboxylic acid 54 46 
 
 
 
A solution of infraluciferin methyl ester 106 (50 mg, 0.156 mmol) in 
THF/H2O (2.4/1.2 mL) was treated with LiOH (8 mg, 0.372 mmol).  After 
stirring at rt for 5 min H2O (20 mL) was added and the aqueous solution 
was washed with EtOAc (20 mL).  The aqueous phase was then made basic 
(pH 3) with 2M HCl, and then extract with EtOAc (20 mL x 3).  The 
organic extractions were combined and dried with MgSO4 filtered and 
concentrated to give infraluciferin 544 as a free flowing orange powder (44 
mg, 92 %). 
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1H NMR (600 MHz, MeOD) δ 7.82 (d, J = 8.9 Hz, 1H), 7.40 (d, J = 16.1 
Hz, 1H), 7.31 (d, J = 2.5 Hz, 1H), 7.30 (d, J = 16.1 Hz, 1H), 7.03 (dd, J = 
8.9, 2.4 Hz, 1H), 5.30 (t, J = 9.0 Hz, 1H), 3.76 – 3.66 (m, 2H).  1H NMR 
data was in agreement with the literature. 
 
 
benzo[d]thiazol-6-amine 143a 87 
 
A solution of HCl (3 mL, 34 mmol) in EtOH/H2O (80/20 mL) was added 6-
nitrobenzothiazole 143 (3.90 g, 21.65 mmol) and iron powder (5.6 g, 101 
mmol).  After stirring at 114 °C for 2 the solution was filtered and rinsed 
with EtOH.  A solution of 10 % NaCO3/H2O was added and then extracted 
with EtOAc.  The organic extractions were combined and dried with 
MgSO4 filtered and concentrated to give 143a as abrown solid (3.25 g, 82 
% lit 92%). 
1HNMR (400 MHz, CDCl3) d 8.70 (s, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.17 
(d, J = 2.4 Hz, 1H), 6.87 (dd, J = 8.8, 2.4 Hz, 1H), 3.85 (br s, 2H).  1H 
NMR data was in agreement with the literature. 
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N,N-dimethylbenzo[d]thiazol-6-amine 143b 87 
 
 
To a solution of 6-aminobenzothiazole 143a (2.68 g, 17.84 mmol) in THF 
(70 mL) was added formaldehyde/H2SO4 (13/14 mL) iron powder (7.97 g, 
143 mmol) was then added and the mixture was stirred at rt for 3.5 h.  
NaOH/H2O (5 g / 90 mL) was added to the reaction mixture until basic.   
The aqueous phase was extracted with EtOAc and the organic phase dried 
with MgSO4 and concentrated in vacuo to give 4.25 g of orange/brown 
waxy solid.   Purification was achieved by flash chromatography (1:1 
EtOAc/Hex) to give 143b (680 mg, 22 %) as white crystals. 
1H NMR (400 MHz, CDCl3) d 8.67 (s, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.15 
(d, J = 2.4 Hz, 1H), 7.00 (dd, J = 8.8, 2.4 Hz, 1H), 3.04 (s, 6H). 1H NMR 
data was in agreement with the literature. 
 
 
 
 
6-(dimethylamino)benzo[d]thiazole-2-carbaldehyde 140 87 
S
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A solution of n-BuLi  (3.98 mmol) in THF (12 mL) was cooled to -78 °C 
and a solution of 143b (676 mg, 3.79 mmol) in THF (6 mL) was added 
drop wise and the mixture warmed to -50 °C for 1 h.  The reaction mixture 
was cooled to -78 °C and DMF (1.17 mL, 15 mmol) was added dropwise 
and the reaction was stirred at -78 °C for 2 h.  The reaction was quenched 
with H2O (35 mL) and extracted with DCM (50 mL x 3).  The organic 
phase dried with NaSO4 and concentrated in vacuo to give 140 (760 mg, 82 
%) of orange crystals which were >95 % pure by 1H NMR 
1H NMR (400 MHz, CDCl3) d 10.06 (s, 1H), 8.03 (d, J = 10.0 Hz, 1H), 
7.07– 7.04 (m, 2H), 3.12 (s, 6H) 1H NMR data was in agreement with the 
literature. 
 
 
 Methyl-(E)-(3-(6-(dimethylamino)benzo[d]thiazol-2-yl)prop-
2enethioyl)serinate 141 
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A solution 124 methyl 2-(2-(diethoxyphosphoryl)ethanethioamido)-3-
hydroxypropanoate (68 mg, 0.22 mmol) in MeCN (1 mL) was treated with  
DBU (36 mg, 0.24 mmol) and LiCl 10 mg, 0.24 mmol).  After stirring at rt 
for 5 min a solution of 140 in MeCN (1 mL) was added drop wise and 
stirred as rt for 3.5 hrs.  The solution was filtered and concentrated in 
vacuo.  Purification was achieved by flash chromatography (1:1 
EtOAc/Hex) to give 141 (27 mg, 34 %) as an orange oil 
1H NMR (600 MHz, CDCl3) δ 8.13 (s, 1H, CHAr), 9.95 (d, J = 15.6 Hz, 
1H, CHCH), 7.86 (d, J = 9.4 Hz, 1H, CHAr), 7.16 (d, J = 15.6 Hz, 1H, 
CHCH), 6.97 (d, J = 11.2, 1H, CHAr), 5.46 (s, 1H, CHNH), 4.16 (m, 2H, 
CHCH2OH), 3.86 (s, 3H, OCH3), 3.06 (s, 6H, CH3NCH3. m/z (EI) 220 M+ 
HRMS C16H19N3O3S2 calcd. 366.0946, found 366.0950 
 
methyl (E)-2-(2-(6-(dimethylamino)benzo[d]thiazol-2-yl)vinyl)-4,5-
dihydrothiazole-4-carboxylate 142 
 
A solution of 141 (55 mg, 0.150 mmol) in DCM (15 mL) cooled to 0 °C 
was treated with DAST (80 µL 0.602 mmol).  After stirring at 0 °C for 1 h 
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40 min the reaction was warmed at rt for 15 min and quenched with 
saturated aqueous NH4Cl solution (3.5 mL).  The layers were separated 
and the aqueous layer was re-extracted with DCM (2 × 10 mL). The 
combined organic layers were washed with brine (30 mL), dried Na2SO4, 
and concentrated.  Purification was achieved by flash chromatography (1:1 
EtOAc/Hex) to give 142 (43 mg, 83 %) as an orange waxy solid. 
1H NMR (600 MHz, CDCl3) δ 7.85 (d, J = 9.1 Hz 1H, CHAr), 7.41 (d, J = 
16.1 Hz, 1H, CHCH), 7.24 (d, J = 16.1 Hz, 1H, CHCH), 7.03 (d, J = 2.5 
Hz, 1H, CHAr), 6.95 (dd, J = 9.1 Hz, 2.5 Hz, 1H, CHAr), 5.24 (t, 9.3 Hz 
1H, CHN), 3.86 (s, 3H, OCH3), 3.66 (m, 2H, CHCH2OH), 3.06 (s, 6H, 
CH3NCH3. 13C NMR (151 MHz, CDCl3) δ 171.10 (1C), 169.54 (1C), 
159.25 (1C), 149.67 (1C), 145.76 (1C), 137.76 (1C), 135.64 (1C,CHCH), 
127.70(1C, CHCH), 124.08(1C, CHAr), 113.73(1C, CHAr), 102.28(1C, 
CHAr), 78.24 (1C, CH), 53.09 (1C, CH3), 40.95 (6C, NCH3), 35.01 (1C, 
CH2). m/z (EI) 220 M+ HRMS C16H17N3O2S2 calcd. 348.0840, found 
348.0842 
 
(E)-2-(2-(6-(dimethylamino)benzo[d]thiazol-2-yl)vinyl)-4,5-
dihydrothiazole-4-carboxylic acid 139 
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A solution of 142 (41 mg, 0.118 mmol) in THF/H2O (2.4/1.2 mL) was 
treated with LiOH (12 mg, 0.507 mmol).  After stirring at rt for 5 min H2O 
(20 mL) was added and the aqueous solution was washed with EtOAc (20 
mL).  The aqueous phase was then made basic (pH 3) with 2M HCl, and 
then extract with EtOAc (20 mL x 3).  The organic extractions were 
combined and dried with MgSO4 filtered and concentrated to give 139 as a 
free black solid (35 mg, 90 %). 
1H NMR (600 MHz, CDCl3) δ 7.87 (d, J = 8.5 Hz 1H, CHAr), 7.46 (d, J = 
15.8 Hz, 1H, CHCH), 7.25 (d, J = 15.8 Hz, 1H, CHCH), 7.03 (s, 1H, 
CHAr), 6.96 (dd, J = 8.1 Hz, 2.5 Hz, 1H, CHAr), 5.32 (t, 9.1 Hz1H, 
CHNH), 3.71 (m, 2H, CHCH2OH), 3.06 (s, 6H, CH3NCH3. 13C NMR (151 
MHz, CDCl3) δ 170.02 (1C), 158.81 (1C), 149.25 (1C), 145.74 (1C), 
141.46 (1C), 138.01 (1C), 136.03 (1C,CHCH), 124.19(1C, CHCH), 
119.37(1C, CHAr), 113.65(1C, CHAr), 102.29(1C, CHAr), 78.83 (1C, 
CH), 40.095 (6C, NCH3), 29.83 (1C, CH2). IR νmax (thin film) 2922, 1719, 
1593, 1351, 1200, 906, 729 m/z (EI) 220 HRMS C15H15N3O2S2 calcd. 
334.0684, found 334.0689 
S
N
Me2N N
S
O
OH
University College London 126 
Appendices  
7.1 Abbreviations 
aq.   aqueous 
DCM   dichloromethane 
DMSO  dimethylsulfoxide 
g   gram 
h   hour 
Hz   hertz 
IR   infrared spectroscopy 
M   mole per litre 
Mg   milligram 
MHz   megahertz 
mL   millilitre 
mmol   millimole 
mp   melting point 
MS   mass spectrometry 
NMR   nuclear magnetic resonance 
rt   room temperature 
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